CN111362972B - 一种苯并咪唑并[2,1-b]噻唑类化合物及其应用 - Google Patents
一种苯并咪唑并[2,1-b]噻唑类化合物及其应用 Download PDFInfo
- Publication number
- CN111362972B CN111362972B CN202010347865.0A CN202010347865A CN111362972B CN 111362972 B CN111362972 B CN 111362972B CN 202010347865 A CN202010347865 A CN 202010347865A CN 111362972 B CN111362972 B CN 111362972B
- Authority
- CN
- China
- Prior art keywords
- compound
- dmso
- benzimidazole
- nmr
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title claims description 27
- -1 thiazole compound Chemical class 0.000 title description 109
- 150000003557 thiazoles Chemical class 0.000 claims abstract description 28
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims abstract description 23
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000003112 inhibitor Substances 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000007787 solid Substances 0.000 claims description 86
- 239000000203 mixture Substances 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000012669 liquid formulation Substances 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical group [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 229940001468 citrate Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 2
- 229940001447 lactate Drugs 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 2
- 229960001860 salicylate Drugs 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 55
- 230000000694 effects Effects 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract description 5
- 229940125782 compound 2 Drugs 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 102000001253 Protein Kinase Human genes 0.000 abstract description 4
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- 108060006633 protein kinase Proteins 0.000 abstract description 4
- 230000002255 enzymatic effect Effects 0.000 abstract description 3
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 230000002452 interceptive effect Effects 0.000 abstract description 2
- JYZIHLWOWKMNNX-UHFFFAOYSA-N benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 148
- 238000005160 1H NMR spectroscopy Methods 0.000 description 76
- 238000006243 chemical reaction Methods 0.000 description 45
- 239000007858 starting material Substances 0.000 description 34
- 125000005605 benzo group Chemical group 0.000 description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 25
- 229940125797 compound 12 Drugs 0.000 description 25
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 238000001914 filtration Methods 0.000 description 19
- 125000000586 2-(4-morpholinyl)ethoxy group Chemical group [H]C([H])(O*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000012065 filter cake Substances 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 230000002503 metabolic effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000001035 drying Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000004202 carbamide Substances 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 7
- 229950001626 quizartinib Drugs 0.000 description 7
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 229960001701 chloroform Drugs 0.000 description 5
- 229940125807 compound 37 Drugs 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 4
- 241000396922 Pontia daplidice Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- GGXGVZJHUKEJHO-UHFFFAOYSA-N 5-tert-butyl-1,2-oxazol-3-amine Chemical compound CC(C)(C)C1=CC(N)=NO1 GGXGVZJHUKEJHO-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- IHCQWURUZRYCIU-UHFFFAOYSA-N [1,3]thiazolo[3,2-a]benzimidazole Chemical class C1=CC=C2N3C=CSC3=NC2=C1 IHCQWURUZRYCIU-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical class 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- MBUPVGIGAMCMBT-UHFFFAOYSA-N 2-bromo-1-(4-nitrophenyl)ethanone Chemical compound [O-][N+](=O)C1=CC=C(C(=O)CBr)C=C1 MBUPVGIGAMCMBT-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- APHNQOGPYLTSFX-UHFFFAOYSA-N 3-tert-butyl-1,2-oxazol-5-amine Chemical compound CC(C)(C)C=1C=C(N)ON=1 APHNQOGPYLTSFX-UHFFFAOYSA-N 0.000 description 2
- NBJHDLKSWUDGJG-UHFFFAOYSA-N 4-(2-chloroethyl)morpholin-4-ium;chloride Chemical compound Cl.ClCCN1CCOCC1 NBJHDLKSWUDGJG-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- KZHGPDSVHSDCMX-UHFFFAOYSA-N 6-methoxy-1,3-benzothiazol-2-amine Chemical compound COC1=CC=C2N=C(N)SC2=C1 KZHGPDSVHSDCMX-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 2
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- VYWQTJWGWLKBQA-UHFFFAOYSA-N [amino(hydroxy)methylidene]azanium;chloride Chemical compound Cl.NC(N)=O VYWQTJWGWLKBQA-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- FEHLGOYZDFFMND-UHFFFAOYSA-N cyclopropane-1,1-dicarboxamide Chemical compound NC(=O)C1(C(N)=O)CC1 FEHLGOYZDFFMND-UHFFFAOYSA-N 0.000 description 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011257 shell material Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical group OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 description 1
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 1
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- FCKPMFCYLRAGSW-UHFFFAOYSA-N 2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazol-6-ol Chemical compound C=1C(O)=CC=C(N2C=3)C=1SC2=NC=3C1=CC=C([N+]([O-])=O)C=C1 FCKPMFCYLRAGSW-UHFFFAOYSA-N 0.000 description 1
- ZXGAMGFBMYUNHX-UHFFFAOYSA-N 2-[4-[(3-methyl-1,2-oxazol-5-yl)carbamoylamino]phenyl]acetic acid Chemical compound CC1=NOC(=C1)NC(NC1=CC=C(C=C1)CC(=O)O)=O ZXGAMGFBMYUNHX-UHFFFAOYSA-N 0.000 description 1
- VLNVTNUTGNBNBY-UHFFFAOYSA-N 2-amino-1,3-benzothiazol-6-ol Chemical compound C1=C(O)C=C2SC(N)=NC2=C1 VLNVTNUTGNBNBY-UHFFFAOYSA-N 0.000 description 1
- LJYOFQHKEWTQRH-UHFFFAOYSA-N 2-bromo-1-(4-hydroxyphenyl)ethanone Chemical compound OC1=CC=C(C(=O)CBr)C=C1 LJYOFQHKEWTQRH-UHFFFAOYSA-N 0.000 description 1
- JPTLLABTZRFJGC-UHFFFAOYSA-N 2-ethylpropanediamide Chemical compound CCC(C(N)=O)C(N)=O JPTLLABTZRFJGC-UHFFFAOYSA-N 0.000 description 1
- DFSFLZCLKYZYRD-UHFFFAOYSA-N 3,4-diethoxycyclobut-3-ene-1,2-dione Chemical compound CCOC1=C(OCC)C(=O)C1=O DFSFLZCLKYZYRD-UHFFFAOYSA-N 0.000 description 1
- FNXYWHTZDAVRTB-UHFFFAOYSA-N 3-methyl-1,2-oxazol-5-amine Chemical group CC=1C=C(N)ON=1 FNXYWHTZDAVRTB-UHFFFAOYSA-N 0.000 description 1
- CUMCMYMKECWGHO-UHFFFAOYSA-N 3-methyl-1,2-oxazole Chemical compound CC=1C=CON=1 CUMCMYMKECWGHO-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OTCNMSBJZOJYJL-UHFFFAOYSA-N 4-[(3-methyl-1,2-oxazol-5-yl)carbamoylamino]benzoic acid Chemical compound CC1=NOC(=C1)NC(NC1=CC=C(C(=O)O)C=C1)=O OTCNMSBJZOJYJL-UHFFFAOYSA-N 0.000 description 1
- AFKWOFFTEWQJDS-UHFFFAOYSA-N 4-[(3-tert-butyl-1,2-oxazol-5-yl)carbamoylamino]benzoic acid Chemical compound C(C)(C)(C)C1=NOC(=C1)NC(NC1=CC=C(C(=O)O)C=C1)=O AFKWOFFTEWQJDS-UHFFFAOYSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- VFUYZXMSUPPEGE-UHFFFAOYSA-N 4-[(5-tert-butyl-1,2-oxazol-3-yl)carbamoylamino]benzoic acid Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C(O)=O)=N1 VFUYZXMSUPPEGE-UHFFFAOYSA-N 0.000 description 1
- YGQURMQHUGDYAO-UHFFFAOYSA-N 4-[2-[2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazol-6-yl]oxyethyl]morpholine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=CN2C3=CC=C(OCCN4CCOCC4)C=C3SC2=N1 YGQURMQHUGDYAO-UHFFFAOYSA-N 0.000 description 1
- LJRZEFJDESVBDJ-UHFFFAOYSA-N 4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]aniline Chemical compound C1=CC(N)=CC=C1C1=CN2C3=CC=C(OCCN4CCOCC4)C=C3SC2=N1 LJRZEFJDESVBDJ-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical group NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- YQYGPGKTNQNXMH-UHFFFAOYSA-N 4-nitroacetophenone Chemical compound CC(=O)C1=CC=C([N+]([O-])=O)C=C1 YQYGPGKTNQNXMH-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical group OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- WRDWWAVNELMWAM-UHFFFAOYSA-N 4-tert-butylaniline Chemical group CC(C)(C)C1=CC=C(N)C=C1 WRDWWAVNELMWAM-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- FKPXGNGUVSHWQQ-UHFFFAOYSA-N 5-methyl-1,2-oxazol-3-amine Chemical group CC1=CC(N)=NO1 FKPXGNGUVSHWQQ-UHFFFAOYSA-N 0.000 description 1
- AGQOIYCTCOEHGR-UHFFFAOYSA-N 5-methyl-1,2-oxazole Chemical compound CC1=CC=NO1 AGQOIYCTCOEHGR-UHFFFAOYSA-N 0.000 description 1
- IHYWQSHBHFRFJX-UHFFFAOYSA-N 6-methoxy-2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazole Chemical compound C=1C(OC)=CC=C(N2C=3)C=1SC2=NC=3C1=CC=C([N+]([O-])=O)C=C1 IHYWQSHBHFRFJX-UHFFFAOYSA-N 0.000 description 1
- GPNAVOJCQIEKQF-UHFFFAOYSA-N 6-nitro-1,3-benzothiazol-2-amine Chemical compound C1=C([N+]([O-])=O)C=C2SC(N)=NC2=C1 GPNAVOJCQIEKQF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000008025 Alternanthera ficoidea Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 241001605719 Appias drusilla Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- XOADMGVAANOOCZ-UHFFFAOYSA-N CCOC(=O)c1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1 Chemical compound CCOC(=O)c1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1 XOADMGVAANOOCZ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- MWHAYHHLZAWVDV-UHFFFAOYSA-N Cc1cc(NC(=O)Nc2ccc(CC(O)=O)cc2)no1 Chemical compound Cc1cc(NC(=O)Nc2ccc(CC(O)=O)cc2)no1 MWHAYHHLZAWVDV-UHFFFAOYSA-N 0.000 description 1
- TYQNYKIDNWZARC-UHFFFAOYSA-N Cc1cc(NC(=O)Nc2ccc(cc2)C(O)=O)no1 Chemical compound Cc1cc(NC(=O)Nc2ccc(cc2)C(O)=O)no1 TYQNYKIDNWZARC-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101100335080 Homo sapiens FLT3 gene Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101150097381 Mtor gene Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- MMKBAMFNMISDHA-UHFFFAOYSA-N S1C2N(C=C1)C=CN2N Chemical compound S1C2N(C=C1)C=CN2N MMKBAMFNMISDHA-UHFFFAOYSA-N 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229950009240 crenolanib Drugs 0.000 description 1
- DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- RGBVWCQARBEPPW-UHFFFAOYSA-N cyclobut-3-ene-1,2-dione Chemical compound O=C1C=CC1=O RGBVWCQARBEPPW-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- PQZTVWVYCLIIJY-UHFFFAOYSA-N diethyl(propyl)amine Chemical compound CCCN(CC)CC PQZTVWVYCLIIJY-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- CFNDVXUTYPXOPG-UHFFFAOYSA-N ethyl 2-(4-aminophenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(N)C=C1 CFNDVXUTYPXOPG-UHFFFAOYSA-N 0.000 description 1
- DWDRNKYLWMKWTH-UHFFFAOYSA-N ethyl 2-(4-nitrophenyl)acetate Chemical compound CCOC(=O)CC1=CC=C([N+]([O-])=O)C=C1 DWDRNKYLWMKWTH-UHFFFAOYSA-N 0.000 description 1
- VLDJRRJZCVHLFW-UHFFFAOYSA-N ethyl 2-[4-[(3-methyl-1,2-oxazol-5-yl)carbamoylamino]phenyl]acetate Chemical compound C(C)OC(CC1=CC=C(C=C1)NC(=O)NC1=CC(=NO1)C)=O VLDJRRJZCVHLFW-UHFFFAOYSA-N 0.000 description 1
- ZGFYLNVDBJKHJT-UHFFFAOYSA-N ethyl 2-[4-[(5-tert-butyl-1,2-oxazol-3-yl)carbamoylamino]phenyl]acetate Chemical compound C(C)OC(CC1=CC=C(C=C1)NC(=O)NC1=NOC(=C1)C(C)(C)C)=O ZGFYLNVDBJKHJT-UHFFFAOYSA-N 0.000 description 1
- DIPHTXHJKVZYJV-UHFFFAOYSA-N ethyl 4-[(3-methyl-1,2-oxazol-5-yl)carbamoylamino]benzoate Chemical compound C(C)OC(C1=CC=C(C=C1)NC(=O)NC1=CC(=NO1)C)=O DIPHTXHJKVZYJV-UHFFFAOYSA-N 0.000 description 1
- XSFUSTXAJXCYFV-UHFFFAOYSA-N ethyl 4-[(5-methyl-1,2-oxazol-3-yl)carbamoylamino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)NC1=NOC(C)=C1 XSFUSTXAJXCYFV-UHFFFAOYSA-N 0.000 description 1
- PHWSCBWNPZDYRI-UHFFFAOYSA-N ethyl 4-nitrobenzoate Chemical compound CCOC(=O)C1=CC=C([N+]([O-])=O)C=C1 PHWSCBWNPZDYRI-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229950006304 gilteritinib Drugs 0.000 description 1
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical class 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005482 norpinyl group Chemical group 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical class CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- TXDPLBRYZKTSIW-UHFFFAOYSA-N phenyl n-(3-methyl-1,2-oxazol-5-yl)carbamate Chemical compound O1N=C(C)C=C1NC(=O)OC1=CC=CC=C1 TXDPLBRYZKTSIW-UHFFFAOYSA-N 0.000 description 1
- AOXNEYUOJSRBSQ-UHFFFAOYSA-N phenyl n-(5-methyl-1,2-oxazol-3-yl)carbamate Chemical compound O1C(C)=CC(NC(=O)OC=2C=CC=CC=2)=N1 AOXNEYUOJSRBSQ-UHFFFAOYSA-N 0.000 description 1
- FGUDMROYDQCCNY-UHFFFAOYSA-N phenyl n-(5-tert-butyl-1,2-oxazol-3-yl)carbamate Chemical compound O1C(C(C)(C)C)=CC(NC(=O)OC=2C=CC=CC=2)=N1 FGUDMROYDQCCNY-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
本发明公开了一种苯并咪唑并[2,1‑b]噻唑类化合物及其应用,属于医药技术领域。本发明中合成的苯并咪唑并[2,1‑b]噻唑类似物对FLT3的抑制活性达到90%以上,其中,化合物(化合物2、4、6、8和10)对FLT3‑ITD激酶的IC50值较低,特别是化合物2,其IC50值仅为5.60nM,因此,本发明的化合物可以被用作FLT3的抑制剂,或者用来制备药物,所述药物能够通过影响一种或多种酪氨酸激酶的酶活性并干扰由所述激酶转导的信号来调节或抑制与异常细胞增殖相关的疾病,具有广阔的应用前景。
Description
技术领域
本发明涉及一种苯并咪唑并[2,1-b]噻唑类化合物及其应用,属于医药技术领域。
背景技术
恶性肿瘤的发生、发展是一个复杂的过程,传统的治疗药物主要分烷化剂、抗代谢类药物、天然产物和抗生素等几类,这几类药物的缺点是疗效不明显,毒副作用大。目前小分子激酶抑制剂作为潜在的癌症疗法,是一个让人感兴趣的领域。蛋白激酶是一种催化剂,在细胞生物学和生物化学的几乎每个方面都发挥着关键作用。这些酶产生信号模块,调控细胞周期进展、增殖、程序性细胞死亡(凋亡)、细胞骨架功能、运动、分化、发育、转录和翻译。蛋白激酶的作用众多,对它们进行仔细的调控是至关重要的,因为异常的活动可能引发癌症、心血管疾病、炎症以及神经紊乱。蛋白激酶的失调、过表达和突变在人类疾病的发病机制中起着因果作用,因此这些酶是有吸引力的药物靶点。具有蛋白质酪氨酸激酶(PTKs)活性的生长因子受体被称为受体酪氨酸激酶。蛋白受体酪氨酸激酶是一类受到严格调控的酶,家族中不同成员的异常激活是癌症的标志之一。FLT3与KIT、FMS、血小板衍生生长因子受体(PDGFR)等受体同属于受体酪氨酸激酶家族,这些受体在造血调节中发挥着重要作用。
FLT3是表达在造血干细胞上的特异性细胞因子受体,具有调节造血干祖细胞生存及生长、树突状细胞成熟、维持调节性T细胞稳态等作用。大约30%的急性髓系白血病(AML)患者存在FLT3基因突变的现象,主要包括FLT3内部串联重复(FLT3-ITD)及FLT3酪氨酸激酶结构域点突变(FLT3-TKD)。FLT3-ITD突变导致酪氨酸激酶功能的本构性、配体无关的激活,已知对患者生存预后不良,在AML患者中约占25%,FLT3-TKD约占5%~10%。FLT3可在配体结合上进行二聚并经历自磷酸化,从而启动多个细胞内信号程序。体外实验发现FLT3突变可通过MAPK、PI3K/AKT/Mtor及STAT5下游传导通路起促细胞增殖和抑制细胞凋亡的作用。FLT3突变的高发生率及不良预后提示其可作为AML治疗的重要靶点。
目前已上市的FLT3抑制剂有Quizartinib、Gilteritinib、Sorafenib,Sunitinib和Midostaurin等8个药物。Quizartinib和Gilteritinib属于第二代FLT3抑制剂,具有更高的选择性和单药活性。所有FLT3抑制剂与细胞内TKD的ATP结合位点相互作用,竞争性地抑制ATP结合,从而阻止受体的自磷酸化和下游信号的激活。然而,当受体激活时,I型抑制剂与ATP结合位点结合,而II型抑制剂则与紧挨着ATP结合位点的疏水区域相互作用,只有当受体处于非活性构象时才能进入疏水区域,它们阻止了受体的激活。
因此,我们仍然需要能够有效抑制激酶活性且靶向性更强的化合物。
发明内容
针对上述问题,本发明提供了一种苯并咪唑并[2,1-b]噻唑类似物,其结构如式I或式II所示的化合物或其药学上可接受的盐,具有抑制Fms样酪氨酸激酶3(FLT3)的生物学功能,从而为寻找新的治疗癌症、代谢与免疫疾病、心血管病以及神经性疾病等开辟新途径。
本发明所设计化合物为苯并咪唑并[2,1-b]噻唑类似物,含有脲结构,特别是双芳基脲结构,其中一个芳基为异噁唑、苯基等。恶噁唑被认为是细胞因子产生的阻滞剂,且异噁唑的尿素衍生物被描述为RAF激酶的抑制剂,含有此类结构的化合物被称为p38激酶抑制剂。
本发明的第一个目的是提供一种苯并咪唑并[2,1-b]噻唑类似物,所述类似物的结构式如通式I或通式II所示;
其中:R1选自H、-X、未取代或卤素取代的C1-C8直链或支链烷基,或者未取代或卤素取代的C3-C6环烷基或杂环基,或者-OR2、-NR2R3、-SR2、-(CH2)mC(O)OR2、-OC(O)R2、-(CH2)mC(O)NR2R3、-NR2C(O)R3、-(CH2)mC(S)OR2、-OC(S)R2、-NO2、-CN、-(CH2)mCN;A1、A2分别独立地选自空键、-NR4A3-、-OA3-、-SA3-、-(CH2)nC(O)O(CH2)pA3-、-(CH2)nC(O)NR4(CH2)pA3-、-(CH2)nC(S)(CH2)pA3-、-(CH2)nC(N-OH)(CH2)pA3-;X1、X2分别独立地选自C、N、O、S原子;
其中:R2、R3和R4每一个都独立地选自H、或未取代或卤素取代的C1-C6直链或支链烷基、或者未取代或卤素取代的C3-C5环烷基、或1~4个杂原子取代的脂肪杂环、或-(CH2)qR5;A3选自未取代或1~4个基团取代的4~10个原子的芳基或杂环芳基,其中每一个取代基团独立地选自H、-X、未取代或卤素取代的C1-C8直链或支链烷基或者未取代或卤素取代的C3-C6环烷基或杂环烷基、-OR6、-NR6R7、-SR6、-(CH2)wC(O)OR6、-OC(O)R6、-(CH2)wC(O)NR6R7、-NR6C(O)R7、-(CH2)wC(S)OR6、-OC(S)R6、-(CH2)wC(N-OH)OR6、-OC(N-OH)R6、-NO2、-CN、-(CH2)wCN;X3、X4分别独立地选自-(CH2)z、-(CH2)zNR8-、-(CH2)zO(CH2)z-、-(CH2)zS(CH2)z-;
其中:R5选自未取代或卤素取代的C3-C5环烷基、或1~4个杂原子取代的脂肪杂环;R6、R7和R8独立地选自H、未取代或卤素取代的C1-C6直链或支链烷基,或者未取代或卤素取代的C3-C5环烷基,或者1~4个杂原子取代的脂肪杂环;m、n、p、q、w和z各自独立地选自0、1、2、3和4;X代表卤素,卤素包括氟、氯、溴或碘;
此外,所述苯并咪唑并[2,1-b]噻唑类似物还包括通式I或通式Ⅱ化合物的全部药学上可接受的同位素标记化合物,以及苯并咪唑并[2,1-b]噻唑类似物的盐。
在本发明的一种实施方式中,所述同位素包括氢的同位素,例如2H和3H;碳的同位素,例如11C、13C和14C;氮的同位素,例如13N和15N;氧的同位素,例如15O、17O和18O。用较重的同位素例如氘即2H取代可提供某些治疗优势,其有更好的代谢稳定性,例如,体内半衰期增加或降低了剂量需求。
在本发明的一种实施方式中,所述苯并咪唑并[2,1-b]噻唑类似物的药学可接受的盐为无机盐或有机盐,无机盐包括盐酸盐、氢溴酸盐、氢碘酸盐、高氯酸盐、硫酸盐、硫酸氢盐、硝酸盐、磷酸盐、酸式磷酸盐;有机盐包括甲酸盐、乙酸盐、三氟乙酸盐、丙酸盐、丙酮酸盐、羟乙酸盐、乙二酸盐、丙二酸盐、丁二酸盐、戊二酸盐、富马酸盐、马来酸盐、乳酸盐、苹果酸盐、柠檬酸盐、酒石酸盐、甲磺酸盐、乙磺酸盐、苯磺酸盐、水杨酸盐、对甲苯磺酸盐、抗坏血酸盐。
在本发明的一种实施方式中,R1选自-OR2。
在本发明的一种实施方式中,R2选自-Me、-(CH2)qR5。
在本发明的一种实施方式中,q为2。
在本发明的一种实施方式中,R5选自吗啉、哌嗪、N-甲基哌嗪。
在本发明的一种实施方式中,A1选自空键、-NH2C(O)-p-(C6H4)-、-NH2C(O)-CH2-p-(C6H4)-。
在本发明的一种实施方式中,A2选自空键、3-甲基异噁唑、3-叔丁基异噁唑、5-甲基异噁唑、5-叔丁基异噁唑。
在本发明的一种实施方式中,X1选自C原子。
在本发明的一种实施方式中,X2选自C原子。
在本发明的一种实施方式中,通式I或通式II的化合物可以为以下表1具体化合物:
表1
续表1
本发明的第二个目的是提供一种组合物,所述组合物中含有上述苯并咪唑并[2,1-b]噻唑类似物,还含有至少一种药学可接受的赋形剂、载体和/或稀释剂。
本发明的第三个目的是提供上述苯并咪唑并[2,1-b]噻唑类似物在配制制剂中的应用,所述制剂包括用于口服给药的固体制剂、用于口服给药的液体制剂、用于胃肠外注射的制剂、用于局部给药的制剂四类。
在本发明的一种实施方式中,所述制剂为一种用于口服给药的固体制剂,所述固体制剂的剂型包括但不限于胶囊剂、片剂、丸剂、散剂、颗粒剂;在固体制剂中,所述苯并咪唑并[2,1-b]噻唑类似物或其药学可接受的盐作为活性成分与至少一种常规惰性赋形剂(或载体)混合,例如与柠檬酸钠或磷酸二钙;混合物或与下述成分再进行混合:(1)填料或增溶剂,例如,淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸等;(2)粘合剂,例如,羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖、阿拉伯胶等;(3)保湿剂,例如,甘油等;(4)崩解剂,例如琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些符合硅酸盐和碳酸钠等;(5)缓溶剂,例如石蜡等;(6)吸收加速剂,例如季铵化合物等;(7)润湿剂,例如鲸蜡醇和单硬脂酸甘油酯等;(8)吸附剂,例如,高岭土等;(9)润滑剂,例如,滑石、硬脂酸钙、固体聚乙二醇、十二烷基硫酸钠等。
在本发明的一种实施方式中,所述固体制剂的剂型包括但不限于片剂、糖丸、胶囊剂、丸剂和颗粒剂,上述剂型通过采用包衣和壳材料进行包埋形成,例如采用肠溶衣和其他本领域公知的材料晶型包衣或微囊化,包衣和壳材料中可包含不透明剂;在这种固体制剂中,苯并咪唑并[2,1-b]噻唑类似物或其药学可接受的盐作为活性成分的释放能够以延迟的方式在消化道的某一部分中释放,可采用的包衣和壳材料的为聚合物质和蜡类物质。必要时,活性成分也可与上述惰性赋形剂中的一种或者多种形成微胶囊形式。
在本发明的一种实施方式中,所述制剂为一种用于口服给药的液体制剂,所述液体制剂的剂型包括但不限于药学上可接受的乳液、溶液、悬浮液、糖浆、酊剂;除苯并咪唑并[2,1-b]噻唑类似物或其药学可接受的盐外,液体制剂中还包含本领域中常规采用的惰性稀释剂,例如水和其他溶剂,增溶剂和乳化剂、例如,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油类,特别是棉籽油、花生油、玉米油、橄榄油、蓖麻油、芝麻油等或这些物质的混合物等。除了这些惰性稀释剂外,所述液体制剂中也可包括常规助剂,如润湿剂、乳化剂、悬浮剂、甜味剂、矫味剂和香料等。
在本发明的一种实施方式中,所述悬浮剂包括乙氧基化十八烷醇、聚氧乙烯山梨醇、和脱水山梨醇、微晶纤维素、琼脂,或上述这些物质的混合物。
在本发明的一种实施方式中,所述制剂为一种用于胃肠外注射的制剂,所述用于胃肠外注射的制剂的剂型包括但不限于生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液,以及用于重新溶解成无菌的可注射溶液和分散液的无菌粉末;除苯并咪唑并[2,1-b]噻唑类似物或其药学可接受的盐外,所述的用于胃肠外注射的制剂中还包括适宜的载体、稀释剂、溶剂、赋形剂包括水、乙醇、多元醇及其适宜的混合物。
在本发明的一种实施方式中,所述制剂为一种用于局部给药的制剂,所述用于局部给药的制剂的剂型包括但不限于软膏剂、散剂、栓剂、滴剂、喷射剂和吸入剂;所述用于局部给药的制剂中包括作为活性成分的苯并咪唑并[2,1-b]噻唑类似物或其药学可接受的盐,以及在无菌条件下和生理上可接受的载体及任选的防腐剂、缓冲剂,必要时还包括推进剂。
在本发明的一种实施方式中,所述制剂中苯并咪唑并[2,1-b]噻唑类似物的剂量范围为0.01-2000mg/kg,优选的剂量范围为2.5-1000mg/kg、更优选的剂量范围为5-500mg/kg;然而,给药的剂量将必然取决于被治疗宿主、具体的给药途径、以及正在被治疗的疾病的严重性而变化。
本发明的第四个目的是提供一种制备上述苯并咪唑并[2,1-b]噻唑类似物的方法,所述方法通过以下反应式进行:
其中,R1、A1、A2、X1、X2和L与上述苯并咪唑并[2,1-b]噻唑类似物中的定义相同,R′为烃基或H,当R′为烃基时,i的条件为以下两种中的任意一种:(1)加入4-二甲氨基吡啶、三乙胺和三氯甲烷,控制反应温度为50~65℃,回流反应12~20h;(2)加入异丙醇,控制反应温度为80~85℃,微波反应6~12h;
当R′为H时,i的条件为:加入二异丙基乙胺、2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯和N,N-二甲基甲酰胺,在室温下搅拌过夜。
本发明的第五个目的是提供一种用作FLT3抑制剂的药物,所述药物包含苯并咪唑并[2,1-b]噻唑类似物。
本发明的第六个目的是提供一种由上述苯并咪唑并[2,1-b]噻唑类似物所制备得到的药物,所述药物能够通过影响一种或多种酪氨酸激酶(如FLT3激酶)的酶活性并干扰由所述激酶转导的信号来调节、调节和/或抑制与异常细胞增殖相关的疾病,所述疾病为白血病和实体瘤。
在本发明的一种实施方式中,所述实体瘤包括但不限于:癌、肉瘤、成红细胞瘤、成胶质细胞瘤、脑膜瘤、星形细胞瘤、黑色素瘤和成肌细胞瘤。
在本发明中的一种实施方式中,所述疾病的适应症包括但不限于:卵巢癌、宫颈癌、结直肠癌、乳腺癌、胰腺癌、神经胶质瘤、恶性胶质瘤、黑色素瘤、前列腺癌、白血病、淋巴瘤、非霍奇金淋巴瘤、肺癌、肝细胞癌、胃癌、胃肠道间质瘤、甲状腺癌、胆管癌、子宫内膜癌、肾癌、间变性大细胞淋巴瘤、多发性骨髓瘤、黑色素瘤以及间皮瘤;其中所述的白血病包括急性骨髓性白血病(AML)、B前体细胞急性淋巴细胞性白血病、骨髓增生异常白血病、T细胞急性淋巴细胞性白血病和慢性粒细胞性白血病(CML)。
在本发明中的一种实施方式中,可单独应用上述苯并咪唑并[2,1-b]噻唑类似物或其药学可接受的盐制备药物对FLT3激酶,特别是激活型突变体形式的FLT3、耐药型突变体形式的FLT3进行活性治疗,除此之外,还可以联合常规的同种异基因造血干细胞移植、化学疗法或放射疗法进行治疗;或与其他药学上可接受的治疗剂联合给药,与其他抗肿瘤药物组合,此联合治疗可通过同时、顺序或分开使用治疗的各组分来实现。
在本发明中的一种实施方式中,所述治疗剂和其他抗肿瘤药物包括但不限于:作用于DNA化学结构的抗肿瘤药物:如阿糖胞苷、阿扎胞苷、地西他宾、依托泊苷和;蛋白酶体抑制剂:如伏立诺他、硼替佐米和panobinostat;影响核酸转录的抗肿瘤药物:如伊达比星、柔红霉素、阿霉素、表阿霉素、阿克拉霉素;细胞信号通路抑制剂:如FMS样受体酪氨酸激酶抑制剂舒尼替尼、索拉非尼、吉利替尼、奎扎替尼、来他替尼、米哚妥林、Crenolanib;血管内皮生长因子(VEGF)抑制剂:如西地尼布和塞马西尼;抗肿瘤单抗:如抗GentuzumabOzogamicine抗体、免疫抑制剂PD-1、PD-L1、OX40激动剂抗体;待组合的各成分可同时或顺序的给予,以单一制剂形式或者以不同制剂的形式给予;所述组合不仅包括本发明苯并咪唑并[2,1-b]噻唑类似物的一种及其他活性剂的组合,而且也包括本发明苯并咪唑并[2,1-b]噻唑类似物的两种或更多种与其他活性剂的组合。
本发明的第七个目的是提供所述通式I的化合物在制备食品、保健品方面的应用。
有益效果:
本发明中的苯并咪唑并[2,1-b]噻唑类似物对FLT3的抑制活性达到90%以上。其中,化合物(化合物2、4、6、8和10)对FLT3-ITD激酶的IC50值较低,特别是化合物2的IC50值仅为5.60nM,且上述5个化合物在MV4-11细胞的IC50值均小于2nM,特别是化合物2对MV4-11细胞的IC50值仅为0.176nM。因此,本发明的化合物呈现很好的FLT3的抑制活性,可以被用作FLT3的抑制剂。本发明要求保护的化合物具有很强的药效和对FLT3的选择性。这在开发适于用作FLT3抑制剂的药物方面是有利的。
此外,本发明中制备的化合物还表现出优异的代谢稳定性,所述实施例2表现出大于35小时的代谢半衰期,实施例4和6表现出介于26-35小时的代谢半衰期,相对较长的代谢半衰期使得它们具有降低医疗剂量和扩大给药时间间隔的潜能。
具体实施方式
以下实施例中所用的“烷基”是指直链或支链饱和烃基基团。烷基基团可具有1至10个碳原子(例如1至8个碳原子),烷基基团包括甲基(Me)、乙基(Et)、丙基(例如,正丙基和异丙基)、丁基(例如,正丁基、异丁基、仲丁基、叔丁基)、戊基基团(例如,正戊基、异戊基、新戊基)、己基(例如,正己基及其异构体)等。其中,低级烷基基团一般最多有4个碳原子。低级烷基基团包括甲基、乙基、丙基(例如正丙基和异丙基)和丁基基团(例如正丁基、异丁基、仲丁基、叔丁基)。在一个实施例中一个烷基基团或两个或多个烷基基团可形成桥连的烷基基团,即其中烷基基团经另一个基团连接(特别显示于环状基团),通过烷基链桥连形成环,即形成桥连的稠合环。
以下实施例中所用的“环烷基”是指非芳香碳环基团,包括环状烷基、链烯基和炔基基团。环烷基基团可以是单环(例如环己基)或多环(例如,包含稠合、桥连和/或螺环体系),其中碳原子位于环体系内部或外部。环烷基基团作为整体可具有3至14个环原子(例如,3至8个碳原子用于单环环烷基基团和7至14个碳原子用于多环环烷基基团)。环烷基基团包括环丙基、环丁基、环戊基、环己基、环庚基、环戊烯基、环己烯基、环己二烯基、环庚三烯基、冰片基、norpinyl、norcaryl、金刚烷基和螺[4.5]癸基,及其同系物、异构体等。
以下将通过实施例详细描述化合物1-40的合成方法。
中间体2a 2-氨基-6-羟基苯并噻唑
将2-氨基-6-甲氧基苯并噻唑(18.02g,100mmol)混悬于40%溴化氢水溶液(140ml)中,120℃下搅拌反应4h。将体系降温至0℃,过滤,滤饼用饱和NaHCO3水溶液调pH至8~9,过滤,40℃真空干燥8h,得白色固体2a(14.46g,87.1%)。MS-ESI(m/z):167.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ7.12(d,1H),7.06(s,2H),7.01(d,1H),6.64(dd,1H)。
中间体3a 2-(4-硝基苯基)苯并[d]咪唑并[2,1-b]噻唑-7-醇
将中间体2a(14.13g,85.0mmol)、2-溴-4'-硝基苯乙酮(22.82g,93.5mmol)和NaHCO3(7.85g,93.4mmol)混悬于正丁醇(n-BuOH,280mL)中,回流反应3h。反应结束后冷却至室温,加入丙酮-水(150mL,丙酮:水=1:3(v/v))的混合溶剂,并于0℃搅拌1h,抽滤,滤饼用水洗涤,干燥,得黄色固体3a(22.83g,86.3%)。MS-ESI(m/z):312.0[M+H]+。1H NMR(400MHz,DMSO-d6)δ9.96(s,1H),8.93(s,1H),8.27(d,2H),7.78(d,1H),7.38(d,1H),6.97(dd,1H)。
中间体3b 4-(7-硝基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯酚
将2-氨基-6-硝基苯并噻唑(6.84g,35.0mmol)、2-溴-4'-羟基苯乙酮(8.28g,38.5mmol)和NaHCO3(3.23g,38.4mmol)混悬于n-BuOH(140mL)中,回流反应3h。反应结束后冷却至室温,加入丙酮-水(75mL,丙酮:水=1:3(v/v))的混合溶剂,并于0℃搅拌1h,抽滤,滤饼用水洗涤,干燥,得黄色固体3b(3.53g,32.4%)。MS-ESI(m/z):312.0[M+H]+。1H NMR(400MHz,DMSO-d6)δ9.59(s,1H),9.10(d,J=2.4Hz,1H),8.45(dd,J=8.9,2.4Hz,1H),8.10(dd,J=8.9,2.5Hz,1H),7.74–7.66(m,2H),7.42(d,J=8.9Hz,1H),6.89–6.80(m,2H)。
中间体3c 7-甲氧基-2-(4-硝基苯基)苯并[d]咪唑并[2,1-b]噻唑
将2-氨基-6-甲氧基苯并噻唑(3.60g,20.0mmol)、2-溴-4'-硝基苯乙酮(5.37g,22.0mmol)和NaHCO3(1.85g,22.0mmol)混悬于n-BuOH(72mL)中,回流反应3h。反应结束后冷却至室温,加入丙酮-水(80mL,丙酮:水=1:3(v/v))的混合溶剂,并于0℃搅拌1h,抽滤,滤饼用水洗涤,干燥,得黄色固体3c(4.38g,67.3%)。MS-ESI(m/z):326.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ8.94(s,1H),8.27(d,J=8.4Hz,2H),8.04(d,J=8.5Hz,2H),7.88(d,J=8.8Hz,1H),7.67(d,J=2.5Hz,1H),7.16(dd,J=8.8,2.5Hz,1H),3.83(s,3H)。
中间体4a 4-(2-((2-(4-硝基苯基)苯并[d]咪唑并[2,1-b]噻唑-7-基)氧基)乙基)吗啉
将中间体3a(21.79g,70.0mmol)、N-2-氯乙基吗啉盐酸盐(32.56g,104.6mmol)、碳酸铯(57.02g,175.0mmol)和四丁基碘化铵(5.17g,14.0mmol)混悬于二甲基亚砜(DMSO,425mL)中,90±5℃搅拌1h,然后将体系115℃搅拌反应6h。将体系降温至室温,量取水(153mL)和丙酮(305mL)加入到体系中,并于室温搅拌2h。过滤,滤饼用水和丙酮洗涤,50℃真空干燥得黄色固体4a(26.83g,收率90.3%)。ESI-MS(m/z):425.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ:9.00(s,1H),8.30(d,J=8.8Hz,2H),8.08(d,J=8.8Hz,2H),7.91(d,J=8.8Hz,1H),7.72(d,J=2.4Hz,1H),7.20(dd,J=2.8、9.2Hz,2H),4.17(t,J=5.6Hz,2H),3.59(t,J=4.8Hz,4H),2.73(t,J=6.0Hz,2H)。
中间体4b 4-(2-(4-(7-硝基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯氧基)乙基)吗啉
将中间体3b(3.11g,10.00mmol)、N-(2-氯乙基)吗啉盐酸盐(4.66g,25.03mmol)、碳酸铯(9.79g,30.05mmol)和四丁基碘化铵(0.74g,3.00mmol)混悬于DMSO(30mL)中,90±5℃搅拌1h,然后将体系115℃搅拌反应h。将体系降温至室温,量取21mL水和42mL丙酮加入到体系中,并于室温搅拌2h。过滤,滤饼用水和丙酮洗涤,50℃真空干燥得浅橙黄色固体4b(3.96g,93.3%)。MS-ESI(m/z):425.1[M+H]+。1H NMR(400MHz,CDCl3-d)δ8.64(d,J=2.2Hz,1H),8.37(dd,J=8.9,2.2Hz,1H),7.91(s,1H),7.83–7.73(m,2H),7.68(d,J=8.9Hz,1H),6.99–6.94(m,2H),4.16(t,J=5.7Hz,2H),3.77–3.73(m,4H),2.84(t,J=5.7Hz,2H),2.61(dd,J=5.6,3.5Hz,4H)。
中间体5a 4-[7-[2-(4-吗啉基)乙氧基]咪唑并[2,1-b][1,3]苯并噻唑-2-基]苯胺
将中间体4a(26.32g,62.0mmol)、铁粉(17.36g,310.0mmol)和NH4Cl(23.22g,434.0mmol)混悬于乙醇和水的混合溶剂中(210mL,EtOH:H2O=3:1(v/v)),于90℃反应2.5h。用饱和Na2CO3水溶液调pH至8左右,并加入EtOAc(160mL)稀释,过滤,滤液于50℃减压浓缩除去有机溶剂,残留物加入90mL EtOAc(80mL×3)萃取三次,有机相经无水Na2SO4干燥、过滤,于50℃减压浓缩得黄色固体5a(22.26g,91.0%)。ESI-MS m/z::395.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ8.37(s,1H),7.82(d,J=8.8Hz,1H),7.66(d,J=2.5Hz,1H),7.55–7.44(m,2H),7.14(dd,J=8.8,2.5Hz,1H),6.65–6.55(m,2H),5.17(s,2H),4.15(t,J=5.7Hz,2H),3.59(t,J=4.7Hz,4H),2.72(t,J=5.7Hz,2H)。
中间体5b 2-(4-(2-吗啉基乙氧基)苯基)苯并[d]咪唑并[2,1-b]噻唑-7-胺
将中间体4a(1.18g,2.8mmol)、铁粉(0.78g,13.9mmol)和NH4Cl(1.04g,19.4mmol)混悬于乙醇和水的混合溶剂中(8mL,EtOH:H2O=3:1(v/v)),于90℃反应2.5h。用饱和Na2CO3水溶液调pH至8左右,并加入EtOAc(8mL)稀释,过滤,滤液于50℃减压浓缩除去有机溶剂,残留物加入90mL EtOAc(4mL×3)萃取三次,有机相经无水Na2SO4干燥、过滤,于50℃减压浓缩得黄色固体5b(923.1mg,83.6%)。MS-ESI(m/z):395.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ8.42(s,1H),7.76–7.71(m,2H),7.59(d,J=8.6Hz,1H),7.04(d,J=2.1Hz,1H),6.98(d,J=8.8Hz,2H),6.74(dd,J=8.6,2.2Hz,1H),5.39(s,2H),4.11(t,J=5.8Hz,2H),3.58(t,J=4.6Hz,4H),2.70(t,J=5.7Hz,2H)。
中间体5c 4-(7-甲氧基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯胺
将中间体3c(3.90g,12.0mmol)、铁粉(3.36g,60.0mmol)和NH4Cl(4.49g,83.9mmol)混悬于乙醇和水的混合溶剂中(28mL,EtOH:H2O=3:1(v/v)),于90℃反应2.5h。用饱和Na2CO3水溶液调pH至8左右,并加入EtOAc(25mL)稀释,过滤,滤液于50℃减压浓缩除去有机溶剂,残留物加入90mL EtOAc(12.5mL×3)萃取三次,有机相经无水Na2SO4干燥、过滤,于50℃减压浓缩得黄色固体5b(3.00g,84.7%)。MS-ESI(m/z):296.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ8.38(s,1H),7.84(d,J=8.8Hz,1H),7.65(d,J=2.5Hz,1H),7.55–7.47(m,2H),7.13(dd,J=8.8,2.6Hz,1H),6.64–6.57(m,2H),5.19(s,2H),3.83(s,3H)。
中间体6a 苯基[5-(叔丁基)异噁唑-3-基]氨基甲酸酯
将3-氨基-5-叔丁基异唑(2.80g,20mmol)溶于无水四氢呋喃(28ml)中,加入碳酸钾(3.59g,26mmol),搅拌下加入氯甲酸苯酯(3.44g,22.0mmol),室温搅拌反应4h。过滤,滤饼用无水四氢呋喃洗涤,滤液于40℃减压浓缩,残留物加入水(35ml)和乙醇(9ml)打浆,室温搅拌3h,过滤,滤饼35℃减压干燥12h,得白色固体6a(5.02g,96.5%)。ESI-MS(m/z):261.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ:11.17(s,1H),7.44(t,J=7.6Hz,2H),7.28(t,J=7.6Hz,1H),7.22(d,J=8.0Hz,2H),6.44(s,1H),1.29(s,9H)。
中间体6b 苯基(5-甲基-1,2-噁唑-3-基)氨基甲酸酯
化合物6b的合成方法参照化合物6a,区别在于将3-氨基-5-叔丁基异唑替换为3-氨基-5-甲基异唑。得白色固体8.10g,收率82.6%。ESI-MS(m/z):219.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ11.10(s,1H),7.47–7.40(m,2H),7.30–7.25(m,1H),7.24–7.19(m,2H),6.47(s,1H),2.37(s,3H)。
中间体6c 苯基(3-(叔丁基)异噁唑-5-基)氨基甲酸酯
将5-氨基-3-叔丁基异唑(2.10g,15mmol)溶于无水四氢呋喃(28ml)中,加入碳酸钾(2.70g,19.5mmol),搅拌下加入氯甲酸苯酯(2.58g,16.5mmol),室温搅拌反应12h。过滤,滤饼用无水四氢呋喃洗涤,滤液于40℃减压浓缩,加入硅胶拌样,柱层析(洗脱剂:PE:EtOAc=20:1~5:1)得浅橙色固体6c(3.40g,87.2%)。ESI-MS(m/z):261.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ:11.17(s,1H),7.69(t,J=7.6Hz,2H),7.31(t,J=7.2Hz,1H),7.23(d,J=8.0Hz,2H),6.44(s,1H),1.30(s,9H)。
中间体6d(3-甲基异噁唑-5-基)氨基甲酸苯酯
化合物6d的合成方法参照化合物6c,区别在于将5-氨基-3-叔丁基异唑替换为5-氨基-3-甲基异唑。色固体1.04g,收率23.9%。ESI-MS(m/z):219.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ11.84(s,1H),7.47–7.41(m,2H),7.29(t,J=7.3Hz,1H),7.27–7.22(m,2H),5.95(s,1H),2.18(s,3H)。
中间体7a(4-硝基苯基)乙酸乙酯
将对硝基苯乙酸(5.43g,30.00mmol)混悬于60mL EtOH中,量取6.60mL(10.76g,90.42mmol)二氯亚砜于冰水浴下滴加到反应体系中,滴加完毕,于室温搅拌反应1.5h。将体系中溶剂于50℃减压浓缩除去,残余物经硅胶柱层析[洗脱剂:石油醚:乙酸乙酯=10:1~5:1(v/v)]纯化,得略带黄色固体7a(6.19g,收率98.6%)。MS-ESI(m/z):210.1[M+H]+。1HNMR(400MHz,DMSO-d6)δ8.20(d,J=8.7Hz,2H),7.57(d,J=8.7Hz,2H),4.10(q,J=7.1Hz,2H),3.88(s,2H),1.19(t,J=7.1Hz,3H)。
中间体7b 4-硝基苯甲酸乙酯
中间体7b的合成参照中间体7a,区别在于将对硝基苯乙酸替换为对硝基苯甲酸。得淡黄色固体5.62g,收率72%。MS-ESI(m/z):196.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ8.38–8.32(m,2H),8.23–8.16(m,2H),4.38(q,J=7.1Hz,2H),1.35(t,J=7.1Hz,3H)。
中间体8a(4-氨基苯基)乙酸乙酯
将中间体7a(6.00g,28.68mmol)溶于MeOH(60mL)中,再加入Pd/C(0.96g,9.02mmol),氢气氛围下于室温搅拌过夜。硅藻土助滤,于50℃减压浓缩,得米色固体8a(5.03g,98%)。MS-ESI(m/z):180.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ6.94–6.85(m,2H),6.53–6.46(m,2H),4.95(s,2H),4.04(q,J=7.1Hz,2H),3.41(s,2H),1.16(t,J=7.1Hz,3H)。
中间体8b 4-氨基苯甲酸乙酯
中间体8b的合成参照中间体8a,区别在于将中间体7a替换为中间体7b。得浅橙色固体4.32g,收率93%。MS-ESI(m/z):166.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ7.63(d,J=8.7Hz,2H),6.56(d,J=8.7Hz,2H),5.95(s,2H),4.19(q,J=7.1Hz,2H),1.26(t,J=7.1Hz,3H).
中间体9a 2-(4-(3-(5-叔丁基异噁唑-3-基)脲基)苯基)乙酸乙酯
将化合物8a(358.2mg,2.0mmol)溶于5mL三氯甲烷中,再加入4-二甲氨基吡啶(14.7mg,0.1mmol)和6a(572.6mg,2.2mmol),于搅拌下滴加3滴三乙胺到反应体系中,滴加完毕将体系50℃搅拌反应过夜。将体系中溶剂于50℃减压浓缩除去,残余物经硅胶柱层析[洗脱剂:石油醚:乙酸乙酯=10:1~5:1(v/v)]纯化,得白色固体9a(575.0mg,83.2%)。MS-ESI(m/z):346.1[M+H]+。1H NMR(300MHz,DMSO-d6)δ9.51(s,1H),8.82(s,1H),7.46–7.38(m,2H),7.21(d,J=8.6Hz,2H),6.52(s,1H),4.10(q,J=7.1Hz,2H),3.62(s,2H),1.32(s,9H),1.21(t,J=7.1Hz,3H)。
中间体9b 2-(4-(3-(5-甲基异噁唑-3-基)脲基)苯基)乙酸乙酯
中间体9b合成参照中间体9a,区别在于将中间体6a替换为中间体6b。得白色固体9b(506.3mg,55.7%)。MS-ESI(m/z):304.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ9.42(s,1H),8.79(s,1H),7.38(d,J=8.5Hz,2H),7.18(d,J=8.4Hz,2H),6.53(s,1H),4.07(q,J=7.1Hz,2H),3.59(s,2H),2.36(s,3H),1.18(t,J=7.1Hz,3H)。
中间体9c 2-(4-(3-(3-(3-(叔丁基)异噁唑-5-基)脲基)苯基)乙酸乙酯
中间体9c合成参照中间体9a,区别在于将中间体6a替换为中间体6c。得白色固体9c(643.5mg,74.5%)。MS-ESI(m/z):346.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.04(s,1H),8.79(s,1H),7.40(d,J=8.5Hz,2H),7.23–7.16(m,2H),6.05(s,1H),4.07(q,J=7.1Hz,2H),3.60(s,2H),1.25(s,9H),1.18(t,J=7.1Hz,3H)。
中间体9d 2-(4-(3-(3-甲基异噁唑-5-基)脲基)苯基)乙酸乙酯
中间体9d合成参照中间体9a,区别在于将中间体6a替换为中间体6d。得白色固体9d(258.9mg,85.3%)。MS-ESI(m/z):304.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.06(s,1H),8.85(s,1H),7.43–7.36(m,2H),7.22–7.17(m,2H),5.95(s,1H),4.07(q,J=7.1Hz,2H),3.60(s,2H),2.16(s,3H),1.18(t,J=7.1Hz,3H)。
中间体9e 4-(3-(5-(叔丁基)异噁唑-3-基)脲基)苯甲酸乙酯
中间体9e合成参照中间体9a,区别在于将中间体8a替换为中间体8b。得白色固体9e(506.3mg,83.2%)。MS-ESI(m/z):332.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ9.63(s,1H),9.17(s,1H),7.90(d,J=8.8Hz,2H),7.61–7.56(m,2H),6.53(s,1H),4.28(q,J=7.1Hz,2H),1.32(t,J=7.1Hz,2H),1.30(s,9H)。
中间体9f 4-(3-(5-甲基异噁唑-3-基)脲基)苯甲酸乙酯
中间体9f合成参照中间体9a,区别在于将中间体8a替换为中间体8b,将中间体6a替换为中间体6b。得白色固体9f(956.5mg,82.7%)。MS-ESI(m/z):290.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ9.57(s,1H),9.18(s,1H),7.94–7.86(m,2H),7.58(d,J=8.8Hz,2H),6.56(d,J=1.0Hz,1H),4.28(q,J=7.1Hz,2H),2.37(s,3H),1.31(t,J=7.1Hz,3H)。
中间体9g 4-(3-(3-(叔丁基)异噁唑-5-基)脲基)苯甲酸乙酯
中间体9g合成参照中间体9a区别在于将中间体8a替换为中间体8b,将中间体6a替换为中间体6c。得白色固体9g(441.5mg,44.4%)。MS-ESI(m/z):332.1[M+H]+。1H NMR(300MHz,DMSO-d6)δ10.25(s,1H),9.26(s,1H),8.09–7.83(m,2H),7.76–7.55(m,2H),6.13(s,1H),4.31(q,J=7.1Hz,2H),1.34(t,J=7.1Hz,3H),1.29(s,9H)。
中间体9h 4-(3-(3-甲基异噁唑-5-基)脲基)苯甲酸乙酯
中间体9h合成参照中间体9a,区别在于将中间体8a替换为中间体8b,将中间体6a替换为中间体6d。得白色固体9h(460.1mg,63.6%)。MS-ESI(m/z):290.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.21(s,1H),9.27(s,1H),7.94–7.88(m,2H),7.62–7.58(m,2H),5.99(s,1H),4.29(q,J=7.1Hz,2H),2.18(s,3H),1.31(t,J=7.1Hz,3H)。
中间体10a 2-(4-(3-(5-(5-(叔丁基)异噁唑-3-基)脲基)苯基)乙酸
将9a(475.0mg,1.4mmol)溶于THF(8.5mL)中,然后加入8.5mL 0.5N NaOH水溶液,反应体系于室温搅拌反应2h。将体系中有机溶剂于40℃减压浓缩除去,加入8.5mL水稀释残余物,向体系中滴加1mmol/L HCl水溶液调pH至3左右,过滤,滤饼于40℃真空干燥4h,得白色固体10a(418.3mg,收率95.6%)。MS-ESI(m/z):318.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ12.27(s,1H),9.46(s,1H),8.78(s,1H),7.40–7.36(m,2H),7.20–7.16(m,2H),6.50(s,1H),3.50(s,2H),1.29(s,9H)。
中间体10b 2-(4-(3-(5-甲基异噁唑-3-基)脲基)苯基)乙酸
中间体10b合成参照中间体10a,区别在于将中间体9a替换为中间体9b。得白色固体10b(348.2mg,95.8%)。MS-ESI(m/z):276.1[M+H]+。1H NMR(300MHz,DMSO-d6)δ9.52(s,1H),8.89(s,1H),7.45–7.33(m,2H),7.24–7.12(m,2H),6.55(s,1H),3.51(s,2H),2.38(s,3H)。
中间体10c 2-(4-(3-(3-(3-(叔丁基)异噁唑-5-基)脲基)苯基)乙酸
中间体10c合成参照中间体10a,区别在于将中间体9a替换为中间体9c。得白色固体10c(569.3mg,76.2%)。MS-ESI(m/z):318.2[M+H]+。1H NMR(300MHz,DMSO-d6)δ12.30(s,1H),10.07(s,1H),8.81(s,1H),7.47–7.37(m,2H),7.30–7.13(m,2H),6.07(s,1H),3.53(s,2H),1.27(s,9H)。
中间体10d 2-(4-(3-(3-甲基异噁唑-5-基)脲基)苯基)乙酸
中间体10d合成参照中间体10a,区别在于将中间体9a替换为中间体9d。得白色固体10d(222.3mg,94.1%)。MS-ESI(m/z):276.2(M+H)+。1H NMR(300MHz,DMSO-d6)δ12.31(s,1H),10.75(s,1H),9.85(s,1H),7.51–7.34(m,2H),7.30–7.10(m,2H),5.95(s,1H),3.52(s,2H),2.18(s,3H)。
中间体10e 4-(3-(5-(叔丁基)异噁唑-3-基)脲基)苯甲酸
中间体10e合成参照中间体10a,区别在于将中间体9a替换为中间体9e。得白色固体10e(302.2mg,82.4%)。MS-ESI(m/z):304.1[M+H]+。1H NMR(300MHz,DMSO-d6)δ12.72(s,1H),9.65(s,1H),9.18(s,1H),7.98–7.83(m,2H),7.67–7.53(m,2H),6.55(s,1H),1.32(s,9H)。
中间体10f 4-(3-(5-甲基异噁唑-3-基)脲基)苯甲酸
中间体10f合成参照中间体10a,区别在于将中间体9a替换为中间体9f。得白色固体10f(256.2mg,70.8%)。MS-ESI(m/z):262.1(M+H)+。1H NMR(300MHz,DMSO-d6)δ12.71(s,1H),9.60(s,1H),9.18(s,1H),7.96–7.86(m,2H),7.64–7.54(m,2H),6.58(d,J=1.0Hz,1H),2.40(s,3H)。
中间体10g 4-(3-(3-(叔丁基)异噁唑-5-基)脲基)苯甲酸
中间体10g合成参照中间体10a,区别在于将中间体9a替换为中间体9g。得白色固体10g(213.6mg,76.8%)。MS-ESI(m/z):304.1[M+H]+。1H NMR(300MHz,DMSO-d6)δ12.64(s,1H),10.85–10.76(m,1H),10.21(s,1H),7.95–7.88(m,2H),7.64–7.57(m,2H),6.09(s,1H),1.28(s,9H)。
中间体10h 4-(3-(3-甲基异噁唑-5-基)脲基)苯甲酸
中间体10h合成参照中间体10a,区别在于将中间体9a替换为中间体9h。得白色固体10h(260.2mg,72.0%)。MS-ESI(m/z):262.1(M+H)+。1H NMR(400MHz,DMSO-d6)δ12.68(s,1H),10.27(s,1H),9.28(s,1H),7.89(d,J=8.4Hz,2H),7.57(d,J=8.4Hz,2H),5.99(s,1H),2.18(s,3H)。
中间体11 1-((4-(7-(2-吗啉基乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)氨基甲酰基)环丙烷-1-甲酸甲酯
将中间体5a(1.18g,3.0mmol)和1,1-环丙基二羧酸单甲酯(432.4mg,3.0mmol)溶于N,N-二甲基甲酰胺(DMF,10mL)中,再加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU,1.31g,3.45mmol),将体系于0℃搅拌10min,加入N,N-二乙基丙胺(DIPEA,829.7mg,6.42mmol),将体系于室温搅拌过夜。将反应液滴加到水(50mL)中,过滤,滤饼用水洗涤,滤饼于40℃真空干燥得橙色固体中间体11(1.38g,88.6%)。MS-ESI(m/z):521.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.02(s,1H),8.80(s,1H),7.87(d,J=2.4Hz,2H),7.80(d,J=3.6Hz,2H),7.66(d,J=3.2Hz,1H),7.53(s,1H),7.00(d,J=5.2Hz,1H),4.07(t,J=4.4Hz,2H),3.66(s,3H),3.57(t,J=4.8Hz,4H),2.69(t,J=3.2Hz,2H),1.68(t,J=2.8Hz,2H),1.43(t,J=3.2Hz,2H)。
中间体12 1-((4-(7-(2-吗啉基乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)氨基甲酰基)环丙烷-1-甲酸
将中间体11(1.30g,2.50mmol)溶于THF(15mL)中,然后加入0.5mmol/L NaOH水溶液(15mL),反应体系于室温搅拌反应2h。将体系中有机溶剂于40℃减压浓缩除去,向体系中滴加1mmol/L HCl水溶液调pH至3左右,过滤,滤饼于40℃真空干燥8h,得白色固体中间体12(1.18g,93.4%)。MS-ESI(m/z):507.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ13.82(s,1H),10.02(s,1H),8.80(s,1H),7.87(d,J=2.4Hz,2H),7.80(d,J=3.6Hz,2H),7.66(d,J=3.2Hz,1H),7.53(s,1H),7.00(d,J=5.2Hz,1H),4.07(t,J=4.4Hz,2H),3.57(t,J=4.8Hz,4H),2.69(t,J=3.2Hz,2H),1.74(t,J=2.8Hz,2H),1.49(t,J=3.2Hz,2H)。
实施例1 1-(5-甲基异噁唑-3-基)-3-[4-(7-(2-吗啉基)乙氧基]苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)脲(化合物1)
将中间体5a(79.1mg,0.20mmol)、6b(48.1mg,0.22mmol)、4-二甲氨基吡啶(DMAP,1.5mg,0.01mmol)依次加入到三氯甲烷(2mL)中,搅拌下加入三乙胺(TEA,3.0mg,0.03mmol),回流反应20h。反应完毕后,冷却至0℃,析出白色固体,继续搅拌2h。抽滤,滤饼用冷的三氯甲烷洗涤,干燥,得白色固体1(84.0mg,80.8%)MS-ESI(m/z):519.3[M+H]+。1HNMR(300MHz,DMSO-d6)δ9.69(s,1H),9.34(s,1H),8.66(s,1H),7.95(d,J=8.9Hz,1H),7.80(d,J=9.6Hz,3H),7.55(d,J=8.2Hz,2H),7.26(d,J=8.9Hz,1H),6.59(s,1H),4.47(s,2H),3.87(s,4H),2.40(s,3H)。
实施例2 1-(3-(叔丁基)异噁唑-5-基)-3-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)尿素(化合物2)
化合物2合成参照化合物1,原料用量的摩尔数相同,区别在于将中间体6b替换为中间体6c。得白色固体60.8mg,收率54.2%。MS-ESI(m/z):561.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ8.93(s,1H),8.61(s,1H),8.15–8.08(m,1H),7.86(d,J=8.8Hz,1H),7.78(d,J=8.3Hz,2H),7.68(d,J=2.4Hz,1H),7.53(d,J=8.4Hz,2H),7.16(dd,J=8.9、2.5Hz,1H),6.08(s,1H),4.16(t,J=5.7Hz,2H),3.59(t,J=4.6Hz,4H),2.97(s,2H),2.73(t,J=5.7Hz,2H),1.27(s,9H)。
实施例2A 1-(3-(叔丁基)异噁唑-5-基)-3-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)尿素盐酸盐(化合物2A)
将实例2(56.1mg)溶解于乙腈(1mL),搅拌下缓慢加入1mol/L HCl(1.5mL),搅拌片刻后冷冻干燥除去溶剂,得淡黄色固体实例2A(58.5mg)。1H NMR(400MHz,D2O)δ9.16(s,1H),8.71(s,1H),8.27–8.20(m,1H),7.79(d,J=8.8Hz,1H),7.84(d,J=8.3Hz,2H),7.78(d,J=2.4Hz,1H),7.65(d,J=7.6Hz,2H),7.26(dd,J=7.7、2.5Hz,1H),6.20(s,1H),4.31(t,J=5.4Hz,2H),3.69(t,J=4.4Hz,4H),2.97(s,2H),2.79(t,J=5.4Hz,2H),1.31(s,9H)。
实施例3 1-(3-甲基异噁唑-5-基)-3-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)脲(化合物3)
化合物3合成参照化合物1,原料用量的摩尔数相同,区别在于将中间体6b替换为中间体6d。得淡黄色固体49.40mg,收率75%。MS-ESI(m/z):519.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.15(s,1H),8.97(s,1H),8.61(s,1H),7.87(d,J=8.8Hz,1H),7.81–7.75(m,2H),7.68(d,J=2.5Hz,1H),7.55–7.49(m,2H),7.16(dd,J=8.9,2.5Hz,1H),5.97(s,1H),4.16(t,J=5.7Hz,2H),3.59(t,J=4.6Hz,4H),2.73(t,J=5.7Hz,2H),2.18(s,3H)。
实施例4 1-(5-(叔丁基)异噁唑-3-基)-3-(2-(4-(2-吗啉代乙氧基)苯基)苯并[d]咪唑并[2,1-b]噻唑-7-基)尿(化合物4)
化合物4合成参照化合物1,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5b,将中间体6b替换为中间体6a。得淡黄色固体40.2mg,收率40.0%。MS-ESI(m/z):561.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.40(s,1H),9.65(s,1H),9.19(s,1H),8.60(s,1H),8.46(d,J=1.9Hz,1H),7.98(d,J=8.4Hz,2H),7.93(d,J=8.7Hz,1H),7.88–7.82(m,1H),7.79(d,J=8.3Hz,2H),7.62(d,J=8.4Hz,2H),7.02(d,J=8.2Hz,2H),6.54(s,1H),4.14(s,2H),3.60(s,4H),2.72(s,2H),1.31(s,9H)。
实施例5 1-(5-甲基异噁唑-3-基)-3-(2-(4-(2-吗啉代乙氧基)苯基)苯并[d]咪唑并[2,1-b]噻唑-7-基)脲(化合物5)
化合物5合成参照化合物1,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5b。得黄色固体45.0mg,收率48.0%。MS-ESI(m/z):519.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.39(s,1H),9.58(s,1H),9.16(s,1H),8.59(s,1H),8.45(d,J=2.0Hz,1H),8.02–7.95(m,2H),7.93(d,J=8.8Hz,1H),7.84(dd,J=8.8,2.1Hz,1H),7.82–7.73(m,2H),7.65–7.57(m,2H),7.02(d,J=8.7Hz,2H),6.57(d,J=1.1Hz,1H),4.14(t,J=5.6Hz,2H),3.60(d,J=4.8Hz,4H),2.73(s,2H),2.38(d,J=0.9Hz,3H),1.23(s,6H)。
实施例6 1-(3-(叔丁基)异噁唑-5-基)-3-(2-(4-(2-吗啉代乙氧基)苯基)苯并[d]咪唑并[2,1-b]噻唑-7-基)尿(化合物6)
化合物6合成参照化合物1,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5b,将中间体6b替换为中间体6c。得黄色固体20.2mg,收率36.3%。MS-ESI(m/z):561.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.40(s,1H),10.22(s,1H),9.18(s,1H),8.59(s,1H),8.45(d,J=2.0Hz,1H),7.98(d,J=8.6Hz,2H),7.93(d,J=8.8Hz,1H),7.84(dd,J=8.9,2.0Hz,1H),7.78(d,J=8.6Hz,2H),7.64(d,J=8.6Hz,2H),7.02(d,J=8.6Hz,2H),6.11(s,1H),4.13(t,J=5.7Hz,2H),3.59(t,J=4.6Hz,4H),2.71(s,2H),1.27(s,9H)。
实施例7 1-(3-甲基异噁唑-5-基)-3-(2-(4-(2-吗啉代乙氧基)苯基)苯并[d]咪唑并[2,1-b]噻唑-7-基)脲(化合物7)
化合物7合成参照化合物1,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5b,将中间体6b替换为中间体6d。得卡其色固体20.3mg,收率25.5%。MS-ESI(m/z):519.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.40(s,1H),10.22(s,1H),9.23(s,1H),8.59(s,1H),8.45(d,J=2.0Hz,1H),7.98(d,J=8.7Hz,2H),7.93(d,J=8.8Hz,1H),7.84(dd,J=8.8,2.0Hz,1H),7.81–7.75(m,2H),7.63(d,J=8.7Hz,2H),7.02(d,J=8.7Hz,2H),6.01(s,1H),4.13(t,J=5.7Hz,2H),3.60(t,J=4.6Hz,4H),2.73(s,2H),2.18(s,3H)。
实施例8 1-(5-(叔丁基)异噁唑-3-基)-3-(4-(7-甲氧基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)脲(化合物8)
将中间体5c(5.92g,15mol)、中间体6a(29g,16.5mol)、DMAP(110.0mg,0.9mmol)依次加入到三氯甲烷(60mL)中,搅拌下加入TEA·(227.7mg,2.25mmol),回流反应20h。反应完毕后,冷却至0℃,析出白色固体,继续搅拌2h。抽滤,滤饼用冷的DCM洗涤,干燥,得白色固体化合物8(51.60mg,收率55.8%)。MS-ESI(m/z):462.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ9.54(s,1H),8.88(s,1H),8.61(s,1H),7.88(d,J=8.8Hz,1H),7.78(d,J=8.1Hz,2H),7.67(s,1H),7.52(d,J=8.2Hz,2H),7.15(d,J=8.9Hz,1H),6.53(s,1H),3.84(s,3H),1.31(s,9H)。
实施例9 1-(4-(7-甲氧基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)-3-(5-甲基异噁唑-3-基)脲(化合物9)
化合物9合成参照化合物8,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5c c,将中间体6a替换为中间体6b。得白色固体42.30mg,收率50.2%。MS-ESI(m/z):420.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ9.48(s,1H),8.89(s,1H),8.60(s,1H),7.88(d,J=8.8Hz,1H),7.78(d,J=8.2Hz,2H),7.67(s,1H),7.51(d,J=8.4Hz,2H),7.15(d,J=8.9Hz,1H),6.56(s,1H),3.84(s,3H),2.38(s,3H)。
实施例10 1-(3-(叔丁基)异噁唑-5-基)-3-(4-(7-甲氧基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)脲(化合物10)
化合物10合成参照化合物8,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5c,将中间体6a替换为中间体6c。得白色固体79.40mg,收率85.4%。MS-ESI(m/z):462.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.13(s,1H),8.89(s,1H),8.62(s,1H),7.88(d,J=8.9Hz,1H),7.79(d,J=8.2Hz,2H),7.53(d,J=8.2Hz,2H),7.15(d,J=8.1Hz,2H),6.75(d,J=7.8Hz,1H),6.08(s,1H),3.84(s,3H),1.27(s,8H)。
实施例11 1-(4-(7-甲氧基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)-3-(3-甲基异噁唑-5-基)脲(化合物11)
化合物11合成参照化合物8,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5c,将中间体6a替换为中间体6d。得白色固体68.20mg,收率80.7%。MS-ESI(m/z):420.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.10(s,1H),8.91(s,1H),8.61(s,1H),7.88(d,J=8.8Hz,1H),7.79(d,J=8.2Hz,2H),7.67(s,1H),7.52(d,J=8.3Hz,2H),7.15(d,J=8.8Hz,1H),5.98(s,1H),3.84(s,3H),2.18(s,3H).
实施例12 2-(4-(3-(5-(叔丁基)异恶唑-3-基)脲基)苯基)-N-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)乙酰胺(化合物12)
将中间体5a(30.8mg,0.08mmol)和中间体10a(24.8mg,0.08mmol)溶于N,N-二甲基甲酰胺(DMF,1.5mL)中,再加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU,34.1mg,0.09mmol),将体系于0℃搅拌10min,加入N,N-丙基乙胺(DIPEA,21.6mg,0.17mmol),将体系于室温搅拌过夜。反应完成后,将反应液滴加到0.25mmol/L的NaOH(15mL)水溶液中,EtOAc(15mL×3)萃取三次,水相用饱和NaCl水溶液(10mL×5)洗涤五次,有机相经无水Na2SO4干燥、过滤,减压浓缩。残余物柱层析(洗脱剂:DCM:MeOH=100:1~20:1)得固体化合物12(42.8mg,79.0%)。MS-ESI(m/z):694.4[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.20(s,1H),9.56(s,1H),8.90(s,1H),8.60(s,1H),7.86(d,J=8.9Hz,1H),7.76(s,2H),7.70–7.62(m,3H),7.45–7.38(m,2H),7.31–7.24(m,2H),7.16(dd,J=8.9,2.5Hz,1H),6.50(s,1H),4.16(t,J=5.7Hz,2H),3.61–3.56(m,6H),2.72(t,J=5.7Hz,2H),1.29(s,9H)。
实施例13 2-(4-(3-(5-甲基异噁唑-3-基)脲基)苯基)-N-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)乙酰胺(化合物13)
化合物13合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体10a替换为中间体10b。得浅橙色固体37.8mg,收率76.0%。MS-ESI(m/z):652.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.19(s,1H),9.41(s,1H),8.79(s,1H),8.60(s,1H),7.86(d,J=8.9Hz,1H),7.77(d,J=8.7Hz,2H),7.70–7.62(m,3H),7.40(d,J=8.6Hz,2H),7.28(d,J=8.4Hz,2H),7.16(dd,J=8.9,2.5Hz,1H),6.53(d,J=1.0Hz,1H),4.16(t,J=5.7Hz,2H),3.63–3.56(m,6H),2.73(d,J=6.4Hz,2H),2.36(d,J=0.9Hz,3H)。
实施例14 2-(4-(3-(3-(叔丁基)异噁唑-5-基)脲基)苯基)-N-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)乙酰胺(化合物14)
化合物14合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体10a替换为中间体10c。得白色固体41.4mg,收率60.0%。MS-ESI(m/z):694.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.20(s,1H),10.04(s,1H),8.80(s,1H),8.60(s,1H),7.86(d,J=8.9Hz,1H),7.81–7.73(m,2H),7.71–7.61(m,3H),7.46–7.39(m,2H),7.29(d,J=8.5Hz,2H),7.16(dd,J=8.9,2.5Hz,1H),6.05(s,1H),4.16(t,J=5.7Hz,2H),3.59(dd,J=8.4,3.7Hz,6H),2.72(t,J=5.7Hz,2H),1.25(s,9H)。
实施例15 2-(4-(3-(3-甲基异噁唑-5-基)脲基)苯基)-N-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)乙酰胺(化合物15)
化合物15合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体10a替换为中间体10d。得白色固体39.1mg,收率54.0%。MS-ESI(m/z):652.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.20(s,1H),10.03(s,1H),8.82(s,1H),8.60(s,1H),7.86(d,J=8.9Hz,1H),7.77(d,J=8.7Hz,2H),7.70–7.63(m,3H),7.44–7.39(m,2H),7.29(d,J=8.5Hz,2H),7.16(dd,J=8.9,2.5Hz,1H),5.95(s,1H),4.16(t,J=5.7Hz,2H),3.63–3.55(m,6H),2.72(s,2H),2.16(s,3H)。
实施例16 4-(3-(5-(叔丁基)异噁唑-3-基)脲基)-N-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)苯甲酰胺(化合物16)
化合物16合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体10a替换为中间体10e。得白色固体28.0mg,收率55.2%。MS-ESI(m/z):680.5[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.20(s,1H),9.64(s,1H),9.13(s,1H),8.64(s,1H),7.97(d,J=8.7Hz,2H),7.90–7.82(m,5H),7.69(d,J=2.5Hz,1H),7.62(d,J=8.8Hz,2H),7.17(dd,J=8.9,2.5Hz,1H),6.55(s,1H),4.17(t,J=5.7Hz,2H),3.60(t,J=4.6Hz,4H),2.73(t,J=5.7Hz,2H),1.31(s,9H)。
实施例17 4-(3-(5-(叔丁基)异噁唑-3-基)脲基)-N-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)苯甲酰胺(化合物17)
化合物17合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体10a替换为中间体10f。得浅橙色固体58.4mg,收率72.1%。MS-ESI(m/z):638.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.19(s,1H),9.60(s,1H),9.20(s,1H),8.64(s,1H),7.96(d,J=8.6Hz,2H),7.91–7.79(m,5H),7.69(d,J=2.5Hz,1H),7.60(d,J=8.6Hz,2H),7.17(dd,J=8.9,2.5Hz,1H),6.58(s,1H),4.17(t,J=5.6Hz,2H),3.59(t,J=4.6Hz,4H),2.73(t,J=5.7Hz,2H),2.38(s,3H)。
实例18 4-(3-(3-(叔丁基)异噁唑-5-基)脲基)-N-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)苯甲酰胺(化合物18)
化合物18合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体10a替换为中间体10g。得浅灰色固体39.6mg,收率57.7%。MS-ESI(m/z):680.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.22(s,1H),10.20(s,1H),9.17(s,1H),8.64(s,1H),7.97(d,J=8.8Hz,2H),7.89–7.80(m,5H),7.69(d,J=2.4Hz,1H),7.63(d,J=8.7Hz,2H),7.17(dd,J=8.8,2.5Hz,1H),6.11(s,1H),4.17(t,J=5.7Hz,2H),3.60(t,J=4.6Hz,4H),2.74(s,2H),1.27(s,9H)。
实施例19 4-(3-(3-甲基异噁唑-5-基)脲基)-N-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)苯甲酰胺(化合物19)
化合物19合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体10a替换为中间体10h。得浅灰色固体41.3mg,收率55.3%。MS-ESI(m/z):638.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.29(s,1H),10.20(s,1H),9.34(s,1H),8.64(s,1H),7.97(d,J=8.8Hz,2H),7.92–7.79(m,5H),7.69(d,J=2.5Hz,1H),7.65–7.58(m,2H),7.23–7.10(m,1H),6.00(s,1H),4.19(d,J=10.7Hz,2H),3.60(s,4H),2.74(s,2H),2.18(s,3H)。
实施例20 2-(4-(3-(5-(叔丁基)异噁唑-3-基)脲基)苯基)-N-(2-(4-(2-吗啉代乙氧基)苯基)苯并[d]咪唑[2,1-b]噻唑-7-基)乙酰胺(化合物20)
化合物20合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5b。得浅黄色固体29.0mg,收率51.7%。MS-ESI(m/z):694.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ9.63(s,1H),9.06(s,1H),8.58(s,1H),8.15(d,J=2.1Hz,1H),7.88(d,J=8.7Hz,1H),7.83–7.71(m,2H),7.57(dd,J=8.7,2.2Hz,1H),7.05–6.96(m,2H),6.52(s,1H),4.12(t,J=5.8Hz,2H),3.59(t,J=4.6Hz,4H),2.71(t,J=5.7Hz,2H),1.30(s,9H)。
实施例21 2-(4-(3-(5-甲基异噁唑-3-基)脲基)苯基)-N-(2-(4-(2-吗啉代乙氧基)苯基)苯并[d]咪唑并[2,1-b]噻唑-7-基)乙酰胺(化合物21)
化合物21合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5b,中间体10a替换为中间体10b。得浅黄色固体45.5mg,收率70.4%。MS-ESI(m/z):652.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ9.58(s,1H),9.07(s,1H),8.58(s,1H),8.14(d,J=2.1Hz,1H),7.87(d,J=8.7Hz,1H),7.81–7.72(m,2H),7.57(dd,J=8.7,2.1Hz,1H),7.06–6.96(m,2H),6.55(s,1H),4.12(t,J=5.8Hz,2H),3.59(t,J=4.6Hz,4H),2.71(t,J=5.7Hz,2H),2.38(s,3H)。
实施例22 2-(4-(3-(3-(叔丁基)异噁唑-5-基)脲基)苯基)-N-(2-(4-(2-吗啉代乙氧基)苯基)苯并[d]咪唑[2,1-b]噻唑-7-基)乙酰胺(化合物22)
化合物22合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5b,中间体10a替换为中间体10c。得白色固体36.4mg,收率52.1%。MS-ESI(m/z):694.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.23(s,1H),9.10(s,1H),8.58(s,1H),8.15(d,J=2.1Hz,1H),7.89(d,J=8.8Hz,1H),7.80–7.74(m,2H),7.60(dd,J=8.7,2.1Hz,1H),7.04–6.98(m,2H),6.08(s,1H),4.12(t,J=5.8Hz,2H),3.59(t,J=4.6Hz,4H),2.71(t,J=5.7Hz,2H),1.27(s,9H)。
实施例23 2-(4-(3-(3-甲基异噁唑-5-基)脲基)苯基)-N-(2-(4-(2-吗啉基乙氧基)苯基)苯并[d]咪唑并[2,1-b]噻唑-7-基)乙酰胺(化合物23)
化合物23合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5b,中间体10a替换为中间体10d。得淡黄色固体41.2mg,收率61.4%。MS-ESI(m/z):652.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.21(s,1H),9.11(s,1H),8.58(s,1H),8.14(d,J=2.1Hz,1H),7.88(d,J=8.7Hz,1H),7.83–7.69(m,2H),7.58(dd,J=8.7,2.2Hz,1H),7.08–6.95(m,2H),5.98(s,1H),4.12(t,J=5.8Hz,2H),3.59(t,J=4.6Hz,4H),2.70(t,J=5.7Hz,2H),2.18(s,3H)。
实施例24 4-(3-(5-(叔丁基)异噁唑-3-基)脲基)-N-(2-(4-(2-吗啉代乙氧基)苯基)苯并[d]咪唑并[2,1-b]噻唑-7-基)苯甲酰胺(化合物24)
化合物24合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5b,中间体10a替换为中间体10e。得淡黄色固体28.0mg,收率41.0%。MS-ESI(m/z):680.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.45(s,1H),9.53(s,1H),8.92(s,1H),8.56(s,1H),8.30(d,J=2.0Hz,1H),7.88(d,J=8.8Hz,1H),7.80–7.73(m,2H),7.66(dd,J=8.8,2.0Hz,1H),7.44–7.40(m,2H),7.29(d,J=8.5Hz,2H),7.03–6.98(m,2H),6.50(s,1H),4.12(t,J=5.8Hz,2H),3.63(s,2H),3.60–3.57(m,4H),2.70(t,J=5.8Hz,2H),1.29(s,9H)。
实施例25 4-(3-(5-甲基异噁唑-3-基)脲基)-N-(2-(4-(2-吗啉代乙氧基)苯基)苯并[d]咪唑并[2,1-b]噻唑-7-基)苯甲酰胺(化合物25)
化合物25合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5b,中间体10a替换为中间体10f。得淡黄色固体46.3mg,收率56.5%。MS-ESI(m/z):638.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.44(s,1H),9.44(s,1H),8.86(s,1H),8.56(s,1H),8.30(d,J=2.0Hz,1H),7.88(d,J=8.7Hz,1H),7.80–7.72(m,2H),7.66(dd,J=8.8,2.1Hz,1H),7.41(d,J=8.6Hz,2H),7.29(d,J=8.5Hz,2H),7.00(d,J=8.8Hz,2H),6.53(d,J=1.0Hz,1H),4.12(t,J=5.8Hz,2H),3.63(s,2H),3.59(t,J=4.7Hz,4H),2.71(s,2H),2.36(d,J=0.9Hz,3H)。
实施例26 4-(3-(3-(叔丁基)异噁唑-5-基)脲基)-N-(2-(4-(2-吗啉代乙氧基)苯基)苯并[d]咪唑并[2,1-b]噻唑-7-基)苯甲酰胺(化合物26)
化合物26合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5b,中间体10a替换为中间体10g。得淡黄色固体38.8mg,收率56.9%。MS-ESI(m/z):680.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.42(s,1H),10.04(s,1H),8.80(s,1H),8.56(s,1H),8.30(d,J=2.0Hz,1H),7.88(d,J=8.8Hz,1H),7.80–7.73(m,2H),7.66(dd,J=8.8,2.0Hz,1H),7.45–7.41(m,2H),7.29(d,J=8.3Hz,2H),7.03–6.98(m,2H),6.05(s,1H),4.12(t,J=5.7Hz,2H),3.63(s,2H),3.59(t,J=4.7Hz,4H),2.71(s,2H),1.25(s,9H)。
实施例27 4-(3-(3-甲基异噁唑-5-基)脲基)-N-(2-(4-(2-吗啉代乙氧基)苯基)苯并[d]咪唑并[2,1-b]噻唑-7-基)苯甲酰胺(化合物27)
化合物27合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5b,中间体10a替换为中间体10h。得淡黄色固体43.4mg,收率53.0%。MS-ESI(m/z):638.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.42(s,1H),10.02(s,1H),8.81(s,1H),8.56(s,1H),8.30(d,J=2.0Hz,1H),7.88(d,J=8.7Hz,1H),7.80–7.73(m,2H),7.66(dd,J=8.8,2.1Hz,1H),7.45–7.39(m,2H),7.29(d,J=8.5Hz,2H),7.01(d,J=8.8Hz,2H),5.95(s,1H),4.12(d,J=6.5Hz,2H),3.63(s,2H),3.59(s,4H),2.71(s,2H),2.16(s,3H)。
实施例28 2-(4-(3-(5-(叔丁基)异噁唑-3-基)脲基)苯基)-N-(4-(7-甲氧基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)乙酰胺(化合物28)
化合物28合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5c。得白色固45.6mg,收率53.4%。MS-ESI(m/z):595.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.20(s,1H),9.46(s,1H),8.78(s,1H),8.60(s,1H),7.87(d,J=8.9Hz,1H),7.77(d,J=8.4Hz,2H),7.66(dd,J=9.6,2.3Hz,3H),7.41(d,J=8.4Hz,2H),7.28(d,J=8.3Hz,2H),7.15(dd,J=8.9、2.5Hz,1H),6.50(s,1H),3.84(s,3H),3.60(s,2H),1.29(s,9H)。
实施例29 N-(4-(7-甲氧基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)-2-(4-(3-(5-甲基异噁唑-3-基)脲基)苯基)乙酰胺(化合物29)
化合物29合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5c,中间体10a替换为中间体10b。得白色固体58.7mg,收率81.9%。MS-ESI(m/z):553.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.20(s,1H),9.42(s,1H),8.82(s,1H),8.60(s,1H),7.87(d,J=8.9Hz,1H),7.79–7.75(m,2H),7.69–7.63(m,3H),7.43–7.38(m,2H),7.28(d,J=8.5Hz,2H),7.15(dd,J=8.9、2.5Hz,1H),6.53(d,J=1.0Hz,1H),3.84(s,3H),3.60(s,2H),2.36(d,J=0.9Hz,3H)。
实施例30 2-(4-(3-(3-(3-(叔丁基)异噁唑-5-基)脲基)苯基)-N-(4-(7-甲氧基苯并[d]咪唑[2,1-b]噻唑-2-基)苯基)乙酰胺(化合物30)
化合物30合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5c,中间体10a替换为中间体10c。得白色固体61.6mg,收率81.8%。MS-ESI(m/z):595.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.20(s,1H),10.04(s,1H),8.80(s,1H),8.60(s,1H),7.87(d,J=8.9Hz,1H),7.80–7.74(m,2H),7.68–7.63(m,3H),7.42(d,J=8.6Hz,2H),7.29(d,J=8.4Hz,2H),7.15(dd,J=8.9、2.5Hz,1H),6.05(s,1H),3.84(s,3H),3.61(s,2H),1.25(s,9H)。
实施例31 N-(4-(7-甲氧基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)-2-(4-(3-(3-甲基异噁唑-5-基)脲基)苯基)乙酰胺(化合物31)
化合物31合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5c,中间体10a替换为中间体10d。得略带红色固体55.7g,收率77.5%。MS-ESI(m/z):553.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.20(s,1H),10.03(s,1H),8.82(s,1H),8.60(s,1H),7.87(d,J=8.9Hz,1H),7.80–7.75(m,2H),7.69–7.63(m,3H),7.42(d,J=8.6Hz,2H),7.29(d,J=8.5Hz,2H),7.15(dd,J=8.9,2.6Hz,1H),5.95(s,1H),3.84(s,3H),3.60(s,2H),2.16(s,3H)。
实施例32 4-(3-(5-(叔丁基)异噁唑-3-基)脲基)-N-(4-(7-甲氧基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)苯甲酰胺(化合物32)
化合物32合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5c,中间体10a替换为中间体10e。得白色固体32.6mg,收率41.9%。MS-ESI(m/z):581.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.19(s,1H),9.63(s,1H),9.12(s,1H),8.64(s,1H),8.01–7.94(m,2H),7.92–7.76(m,5H),7.68(d,J=2.5Hz,1H),7.65–7.57(m,2H),7.16(dd,J=8.9,2.6Hz,1H),6.54(s,1H),3.84(s,3H),1.31(s,9H)。
实施例33 N-(4-(7-甲氧基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)-4-(3-(5-甲基异噁唑-3-基)脲基)苯甲酰胺(化合物33)
化合物33合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5c,中间体10a替换为中间体10f。得略带红色固体14.0g,收率19.6%。MS-ESI(m/z):539.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.19(s,1H),9.61(s,1H),9.22(s,1H),8.64(s,1H),7.99–7.94(m,2H),7.91–7.79(m,5H),7.68(d,J=2.5Hz,1H),7.64–7.58(m,2H),7.16(dd,J=8.9,2.6Hz,1H),6.58(d,J=1.1Hz,1H),3.84(s,3H),2.38(d,J=0.9Hz,3H)。
实施例34 4-(3-(3-(叔丁基)异噁唑-5-基)脲基)-N-(4-(7-甲氧基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)苯甲酰胺(化合物34)
化合物34合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5c,中间体10a替换为中间体10g。得浅橙色色固体23.1mg,收率31.2%。MS-ESI(m/z):581.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.21(d,J=8.1Hz,2H),9.16(s,1H),8.64(s,1H),8.00–7.94(m,2H),7.89(d,J=8.9Hz,1H),7.87–7.80(m,4H),7.68(d,J=2.5Hz,1H),7.65–7.60(m,2H),7.16(dd,J=8.9,2.5Hz,1H),6.11(s,1H),3.84(s,3H),1.27(s,9H)。
实施例35 N-(4-(7-甲氧基苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)-4-(3-(3-甲基异噁唑-5-基)脲基)苯甲酰胺(化合物35)
化合物35合成参照化合物12,原料用量的摩尔数相同,区别在于将中间体5a替换为中间体5c,中间体10a替换为中间体10h。得浅橙色色固体44.6g,收率51.5%。MS-ESI(m/z):539.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.20(d,J=2.4Hz,2H),9.19(s,1H),8.64(s,1H),7.97(d,J=8.5Hz,2H),7.89(d,J=8.9Hz,1H),7.83(d,J=2.2Hz,4H),7.68(d,J=2.5Hz,1H),7.62(d,J=8.7Hz,2H),7.16(dd,J=8.9,2.6Hz,1H),6.01(s,1H),3.84(s,3H),2.18(s,3H)。
实施例36 3-((5-(叔丁基)异噁唑-3-基)氨基)-4-((4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)氨基)环丁-3-烯-1,2-二酮(化合物36)
将3-氨基-5-叔丁基异唑(70.1mg,0.50mmol)溶于无水四氢呋喃(3ml)中,加入碳酸钾(89.8mg,0.65mmol),搅拌下加入方酸二乙酯(93.6mg,0.55mmol),室温搅拌反应12h。过滤,滤饼用无水四氢呋喃洗涤,滤饼35℃真空干燥4h,得白色固体中间体13(65.2mg,49.3%)。将5a(78.9mg,0.20mmol)和中间体11(58.1mg,0.22mmol)混悬于异丙醇(i-PrOH,2mL)中,将体系于85℃微波反应搅拌6h。过滤,滤饼于40℃真空干燥3h,得黄色固体化合物36(23.5mg,19.2%)。MS-ESI(m/z):613.4[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.98(s,1H),10.06(s,1H),8.66(s,1H),7.86(dd,J=11.9,8.5Hz,3H),7.70(d,J=2.1Hz,1H),7.52(d,J=8.3Hz,2H),7.17(d,J=7.9Hz,1H),6.64(s,1H),4.17(t,J=5.6Hz,2H),3.59(t,J=4.7Hz,4H),2.74(t,J=5.8Hz,2H),1.32(s,9H)。
实施例37 N-环丙基-N-(4-(7-(2-吗啉基)乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)丙烷-1,1-二甲酰胺(化合物37)
将中间体12(50.5mg,0.10mmol)和对甲氧基苯胺(12.3mg,0.10mmol)溶于N,N-二甲基甲酰胺(DMF,1.5mL)中,再加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU,43.6mg,0.11mmol),将体系于0℃搅拌10min,加入N,N-二乙基丙胺(DIPEA,27.6mg,0.21mmol),将体系于室温搅拌过夜。将反应液滴加到0.25mmol/L的NaOH(15mL)水溶液中,EtOAc(15mL×3)萃取三次,水相用饱和NaCl水溶液(10mL×5)洗涤五次,有机相经无水Na2SO4干燥、过滤,减压浓缩。残余物DCM:MeOH=10:1混合溶剂复溶,爬大板(展开剂:DCM:MeOH=10:1)得淡黄色固体化合物37(33.5mg,54.76%)。MS-ESI(m/z):612.3[M+H]+。1HNMR(400MHz,DMSO-d6)δ10.22(s,1H),9.84(s,1H),8.63(s,1H),7.86(d,J=8.9Hz,1H),7.82–7.76(m,2H),7.69(dd,J=5.7,3.0Hz,3H),7.55–7.49(m,2H),7.16(dd,J=8.8,2.5Hz,1H),6.92–6.86(m,2H),4.16(t,J=5.7Hz,2H),3.73(s,3H),3.59(t,J=4.7Hz,4H),2.73(t,J=5.7Hz,2H),1.48(s,4H).
实施例38 N-(4-氟苯基)-N-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)环丙烷-1,1-二甲酰胺(化合物38)
化合物38合成参照化合物37,原料用量的摩尔数相同,区别在于将对甲氧基苯胺替换为对氟苯胺。得淡黄色固体62.4mg,收率69.1%。MS-ESI(m/z):600.2[M+H]+。1H NMR(400MHz,DMSO-d6)δ10.21(s,1H),9.88(s,1H),8.63(s,1H),7.86(d,J=8.9Hz,1H),7.81–7.75(m,2H),7.68(dd,J=5.7,3.0Hz,3H),7.60–7.53(m,2H),7.23(dd,J=8.8,2.5Hz,1H),6.94–6.87(m,2H),4.16(t,J=5.7Hz,2H),3.59(t,J=4.7Hz,4H),2.73(t,J=5.7Hz,2H),1.82(t,J=4.7Hz,2H),1.51(t,J=5.7Hz,2H)。
实施例39 1-(吗啉-4-羰基)-N-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)环丙烷-1-甲酰胺(化合物39)
化合物39合成参照化合物37,原料用量的摩尔数相同,区别在于将对甲氧基苯胺替换为吗啉。得淡黄色色固体40.2mg,收率46.9%。MS-ESI(m/z):576.3[M+H]+。1H NMR(400MHz,DMSO-d6)δ9.69(s,1H),8.63(s,1H),7.86(d,J=8.8Hz,1H),7.77(d,J=8.5Hz,2H),7.59–7.50(m,3H),7.18(dd,J=8.9,2.5Hz,1H),4.21(t,J=5.7Hz,2H),3.67–3.44(m,12H),2.80–2.70(m,2H),1.39(q,J=4.1Hz,2H),1.24(d,J=3.2Hz,2H)。
实施例40 N-(4-(叔丁基)苯基)-N-(4-(7-(2-吗啉代乙氧基)苯并[d]咪唑并[2,1-b]噻唑-2-基)苯基)环丙烷-1,1-二甲酰胺(化合物40)
化合物40合成参照化合物37,原料用量的摩尔数相同,区别在于将对甲氧基苯胺替换为4-叔丁基苯胺。得淡黄色色固体44.5mg,收率45.1%。MS-ESI(m/z):638.3[M+H]+。1HNMR(400MHz,DMSO-d6)δ10.35(s,1H),9.94(s,1H),8.63(s,1H),7.86(d,J=8.9Hz,1H),7.78–7.74(m,2H),7.69(dd,J=5.7,3.0Hz,3H),7.56–7.50(m,2H),7.16(dd,J=8.8,2.5Hz,1H),6.95–6.88(m,2H),4.19(t,J=5.7Hz,2H),3.59(t,J=4.7Hz,4H),2.73(t,J=5.7Hz,2H),1.76(t,J=4.7Hz,2H),1.43(t,J=5.7Hz,2H),1.33(s,9H)。
实施例41 化合物活性的验证
1.激酶反应
(1)配制1×Kinase buffer。
(2)化合物的配制:配制受试化合物测试浓度为500nM,复孔检测。在384孔板中稀释成100倍终浓度的100%DMSO溶液。使用分液器Echo 550向目的板OptiPlate-384F转移250nL 100倍终浓度的化合物。阴性对照孔和阳性对照孔中分别加250nl的100%DMSO。
(3)用1×Kinase buffer配制2.5倍终浓度的激酶溶液。
(4)在化合物孔和阳性对照孔分别加10μL的2.5倍终浓度的激酶溶液;在阴性对照孔中加10μL的1×Kinase buffer。
(5)对384孔板进行离心,离心条件为1000rpm离心30秒,振荡混匀后室温孵育10分钟。
(6)用1×Kinase buffer配制25倍终浓度的ATP和15倍终浓度的ATP和Kinasesubstrate 2,混合得到混合溶液。
(7)加入15μL的25/15倍(问题同上)终浓度的ATP和底物的混合溶液,起始反应。
(8)对384孔板进行离心,离心条件为1000rpm离心30秒,振荡混匀后室温孵育40min。
(9)加入30μL终止检测液停止激酶反应,对384孔板进行离心,离心条件为1000rpm离心30秒,振荡混匀。
(10)用Caliper EZ Reader读取转化率。
计算公式:
Inhibition%=(Conversion%max-Conversion%sample)/(Conversion%max-Conversion%min)×100,其中Conversion%max表示阳性对照孔转化率读数,Conversion%sample表示样品转化率读数,Conversion%min表示阴性对照孔转化率读数。
(11)拟合量效曲线
以浓度的log值作为X轴,百分比抑制率为Y轴,采用分析软件GraphPad Prism 5的log(inhibitor)vs.response-Variable slope拟合量效曲线,从而得出各个化合物对酶活性的IC 50值。
拟合公式为:Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))
2.MV4-11细胞增殖抑制活性评价
(1)实验仪器:
电热恒温水浴锅(精宏设备,型号:DK-8D)、灭菌锅(ZEALWAY,型号:GI54DWS)、显微镜(Nikon,型号:ECLIPSE TS100-F)、酶标仪(Bio Tek Epoch,型号:VT05404-0998)、离心机(卢湘仪,型号:TDZ4-WS)、CO2培养箱(Thermo Fisher Scientific,型号:3111)、移液枪(Eppendorf)、电子天平、超净工作台、超低温电冰箱。
(2)实验材料:
①细胞株:人髓性单核白血病细胞MV4-11(目录号:SCSP-5031)购自中国科学院上海干细胞库。
②试剂及耗材:IMDM培养基(with L-glutamine)胎牛血清(四季青)、青霉素与链霉素溶液(Solarbio)、0.25%胰蛋白酶(含EDTA,Solarbio)、磷酸盐缓冲液(PBS,Solarbio)、DMSO(Sigma)、Cell Counting Kit-8细胞培养瓶、离心管、吸管、枪头、96孔板等实验耗材购自NEST生物。
③MV4-11细胞培养基(以100mL为例):IMDM基础培养基89mL+胎牛血清10mL+青霉素链霉素溶液1mL。
(3)实验步骤:
①细胞复苏:从液氮中取出细胞冻存管,迅速放入37℃恒温水浴锅中,不断摇晃使其快速解冻。将细胞悬液加入含5倍体积细胞培养基的离心管中,混匀,转速800rpm离心5min。小心弃去上清,加入5mL配制的完全培养基,轻轻吹匀后加至无菌T25培养瓶中,在37℃,5%CO2条件下培养。
②细胞传代:在显微镜下观察细胞生长情况,当培养72h后使用半换液法进行传代培养。向细胞悬浮液中加入5mL新鲜培养基,混匀后,取5mL加入新的T25培养瓶中,在培养箱中培养。
③接种细胞:取对数生长期的细胞,计数。调整细胞悬液的密度为3×105个/mL,取每孔50μL细胞悬液接种到96孔板中,并设置空白对照孔。
④加药:加入稀释成不同浓度的含药培养基,每孔50μL,并设置阴性对照孔,在37℃,5%CO2条件下培养72小时。
⑤细胞显色:每孔加入10μL CCK-8溶液,在培养箱中孵育4小时。
⑥吸光值读取:充分振荡后用酶标仪在450nM波长下读取吸光值。
⑦抑制率计算:利用GraphPad Prism 5软件计算抑制率,计算公式:细胞生长抑制率%=(1-(实验孔吸光值-空白孔吸光值)/(阴性对照孔吸光值-空白孔吸光值))×100%。
表2化合物激酶和细胞活性数据
化合物 | FLT3-ITD的IC<sub>50</sub>(nM) | MV4-11的IC<sub>50</sub>(nM) |
Quizartinib | 6.51 | 0.836 |
1 | 94.67 | 50.81 |
2 | 5.60 | 0.176 |
3 | 157.05 | 33.09 |
4 | 8.25 | 0.782 |
5 | 82.56 | 39.94 |
6 | 6.83 | 0.614 |
续表2
化合物 | FLT3-ITD的IC50(nM) | MV4-11的IC50(nM) |
Quizartinib | 6.51 | 0.836 |
7 | 109.21 | 88.72 |
8 | 18.31 | 1.632 |
9 | 154.02 | 110.5 |
10 | 20.52 | 1.967 |
11 | 223.06 | 280.3 |
12 | 360.46 | 243.2 |
13 | 356.83 | 232.8 |
14 | 362.88 | 169.2 |
15 | 442.29 | >500 |
16 | 305.43 | 300.2 |
17 | 427.76 | 350.9 |
18 | 319.96 | 192.8 |
19 | 403.53 | 138.6 |
20 | 256.90 | 400.1 |
21 | 306.56 | >500 |
22 | 298.08 | 193.6 |
23 | 308.38 | 199.5 |
24 | 338.66 | 203.9 |
25 | 326.54 | 225.7 |
26 | 342.29 | 260.2 |
27 | 404.14 | 318.2 |
28 | 486.50 | 400.8 |
29 | 473.18 | 299.8 |
30 | 459.86 | 143.5 |
31 | 458.64 | 300.1 |
32 | 377.49 | 310.5 |
33 | 432.60 | 186.2 |
34 | 435.03 | 268.7 |
35 | 429.58 | 333.2 |
36 | 239.93 | 145.3 |
37 | 283.12 | 150.4 |
38 | 300.04 | 119.3 |
39 | 298.36 | 120.3 |
40 | 278.52 | 105.1 |
Quizartinib自Selleckchem公司购得(货号:S1526,批号:S152601)目前FLT3抑制剂主要用于白血病等血液疾病,尤其是急性髓细胞性白血病等恶性肿瘤的治疗,本发明化合物已显示出较强的体外活性。从以上表2可以看出,本发明的化合物(化合物2、4、6、8和10)对FLT3-ITD激酶的IC50值较低,特别是化合物2的IC50值为5.60nM,略优于阳性对照Quizartinib,Quizartinib对FLT3-ITD激酶的IC50值为6.51nM。且上述5个化合物在MV4-11细胞的IC50值均小于2nM,特别是化合物2对MV4-11细胞的IC50值仅为0.176nM,明显优于阳性对照Quizartinib,Quizartinib为0.836nM。因此,本发明的化合物呈现很好的FLT3的抑制活性,可以被用作FLT3的抑制剂。
实施例42 使用人体肝脏微粒体进行化合物稳定性的评价
将实施例1~40中的化合物的肝微粒体酶稳定性与Quizartinib进行比较。
测定系统:实施例1~40中的化合物的代谢稳定性利用由男女混合的肝脏微粒体用1mM NADPH进行试验。样品使用质谱仪进行分析。将HRMS用于确定峰面积响应比率(对应于试验化合物或对照物的峰面积除以分析内标的峰面积)而不运行标准曲线。为了检测到所有的可能代谢物,在适当的m/z范围内进行HRMS扫描。
测定条件:该测定用一次孵育(N=1)进行。将试验化合物在37℃下在含有0.5毫克/毫升肝脏微粒体蛋白的缓冲液中孵育。通过加入辅因子引发反应,并于0、2、4、8、16、24、36、48小时取样,平行孵育阳性对照物(5μM睾丸素)并于0、2、4、8、16、24、36、48小时取样。
测定质量控制:平行进行对照化合物睾丸素以证实(肝脏)微粒体的酶活性。最终时间点后,利用荧光测定法来确认NADPH添加到反应混合物中。对照物的T1/2满足可接受的内标。
分析方法:
液相色谱柱:Thermo BDS Hypersil C18 30X2.0mm,3μm,具有保护柱M.P.,缓冲液:25mM甲酸接缓冲液,pH 3.5;
水相(A):90%水,10%缓冲液;
有机相(B):90%乙腈,10%缓冲液;
流速:300微升/分钟
自动进样器:注射体积10微升
梯度程序参见表3。
表3梯度程序
时间(分钟) | %A | %B |
0.0 | 100 | 0 |
续表3
1.5 | 0 | 100 |
2.0 | 0 | 100 |
2.1 | 100 | 0 |
3.5 | 100 | 0 |
通过使用人体肝微粒体,如本发明中所述实施例2表现出大于35小时的代谢半衰期,实施例4和6表现出介于26-35小时的代谢半衰期,显著大于Quizartinib的18小时的代谢半衰期。结果显示,本实例化合物的代谢稳定性比Quizartinib有所提高,相对较长的代谢半衰期使得它们具有降低医疗剂量和扩大给药时间间隔的潜能。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (6)
2.根据权利要求1所述的苯并咪唑并[2,1-b]噻唑类似物及其药学可接受的盐,其特征在于,所述苯并咪唑并[2,1-b]噻唑类似物的药学可接受的盐为无机盐或有机盐,无机盐为盐酸盐、氢溴酸盐、氢碘酸盐、高氯酸盐、硫酸盐、硫酸氢盐、硝酸盐、磷酸盐、酸式磷酸盐;有机盐为甲酸盐、乙酸盐、三氟乙酸盐、丙酸盐、丙酮酸盐、羟乙酸盐、乙二酸盐、丙二酸盐、丁二酸盐、戊二酸盐、富马酸盐、马来酸盐、乳酸盐、苹果酸盐、柠檬酸盐、酒石酸盐、甲磺酸盐、乙磺酸盐、苯磺酸盐、水杨酸盐、对甲苯磺酸盐、抗坏血酸盐。
3.一种组合物,其特征在于,含有权利要求1~2任一项所述的苯并咪唑并[2,1-b]噻唑类似物及其药学可接受的盐,还含有至少一种药学可接受的赋形剂、载体和/或稀释剂。
4.权利要求1~2任一项所述的苯并咪唑并[2,1-b]噻唑类似物及其药学可接受的盐在配制制剂中的应用,其特征在于,所述制剂包括用于口服给药的固体制剂、用于口服给药的液体制剂、用于胃肠外注射的制剂、用于局部给药的制剂这四类。
5.一种用作FLT3抑制剂的药物,其特征在于,所述药物包含权利要求1~2任一项所述中所述的苯并咪唑并[2,1-b]噻唑类似物及其药学可接受的盐。
6.权利要求1~2任一项所述苯并咪唑并[2,1-b]噻唑类似物及其药学可接受的盐在制备用于治疗白血病或实体瘤的药物中应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010347865.0A CN111362972B (zh) | 2020-04-28 | 2020-04-28 | 一种苯并咪唑并[2,1-b]噻唑类化合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010347865.0A CN111362972B (zh) | 2020-04-28 | 2020-04-28 | 一种苯并咪唑并[2,1-b]噻唑类化合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111362972A CN111362972A (zh) | 2020-07-03 |
CN111362972B true CN111362972B (zh) | 2021-08-24 |
Family
ID=71203799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010347865.0A Active CN111362972B (zh) | 2020-04-28 | 2020-04-28 | 一种苯并咪唑并[2,1-b]噻唑类化合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111362972B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101448843A (zh) * | 2006-03-17 | 2009-06-03 | 埃姆比特生物科学公司 | 用于疾病治疗的咪唑并噻唑化合物 |
WO2019233447A1 (en) * | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
-
2020
- 2020-04-28 CN CN202010347865.0A patent/CN111362972B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101448843A (zh) * | 2006-03-17 | 2009-06-03 | 埃姆比特生物科学公司 | 用于疾病治疗的咪唑并噻唑化合物 |
WO2019233447A1 (en) * | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
Non-Patent Citations (1)
Title |
---|
奎扎替尼的合成;赵宽涛等;《中国医药工业杂志》;20200110;第51卷(第1期);第52页左栏倒数第1段 * |
Also Published As
Publication number | Publication date |
---|---|
CN111362972A (zh) | 2020-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7320823B2 (ja) | プテリジノン誘導体のegfr阻害剤としての使用 | |
EP3985000A1 (en) | 2,4-disubstituted pyrimidine derivative, preparation method for same, and uses thereof | |
EP1741714B1 (en) | Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient | |
EP1870414A1 (en) | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency | |
EP1652847A1 (en) | Quinoline and quinazoline derivatives for the treatment of tumors | |
JP2008505112A (ja) | Chk1の阻害に有用な化合物 | |
WO2013170671A1 (zh) | 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用 | |
EP2896620A1 (en) | Alkynyl heteroaromatic ring compound and application thereof | |
CN110563703B (zh) | 基于crbn配体诱导parp-1降解的化合物及制备方法和应用 | |
EP3792264B1 (en) | Pyrropyrimidine compounds as mnks inhibitors | |
WO2023071314A1 (zh) | Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用 | |
CN111989332B (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
CN112174945B (zh) | 具有抗癌作用的吲唑类化合物及其制备方法和用途 | |
CN108299420B (zh) | 作为选择性雌激素受体下调剂的五环类化合物及其应用 | |
CN111362972B (zh) | 一种苯并咪唑并[2,1-b]噻唑类化合物及其应用 | |
CN108752412B (zh) | 乳香酸衍生物及其应用 | |
CN110305125A (zh) | 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用 | |
CN108164548B (zh) | 嘧啶并吗啉衍生物及其制备方法和用途 | |
CN111247137A (zh) | 一种嘧啶类化合物、其制备方法及其医药用途 | |
CN107001317A (zh) | 高选择性取代嘧啶类pi3k抑制剂 | |
US7893061B2 (en) | Alkyne-substituted pyridone compounds and methods of use | |
CN113354630B (zh) | 一种5,6-二氢苯并[h]喹唑啉类化合物及其应用 | |
CN113773273B (zh) | 苯并异噻唑类化合物及其制备方法和用途 | |
CN110526907A (zh) | 苯并噁嗪酮类衍生物及其应用 | |
CN106674200A (zh) | 一种含有l‑脯氨酰胺片段的化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |